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1 Introduction
The nervous system consists of the central nervous system (CNS) and the peripheral
nervous system (PNS). The CNS is composed of the spinal cord and brain, whereas the
remaining neuronal tissue of the body belongs to the PNS. The skull protects the brain,
which is covered by three meninges: The dura mater is the outer meninx protecting the
inner arachnoidea and pia mater, both forming the subarachnoid space containing the
cerebrospinal fluid (CSF). The CSF regulates the intracranial pressure and maintains
the glymphatic clearance as well as the immunological protection within the ventricals
in the inner part of the brain. Anatomically, the brain can be structured into the telen-,
dien- and mesencephalon, cerebellum, pons and medulla oblongata. The telencephalon,
consists of two cerebral hemispheres, which can be divided into four lobes: i) frontal, ii)
parietal, iii) occipital and iv) temporal lobe containing the hippocampus. As this study
focuses on the hippocampus, it will be explained in further details below.
In the brain diverse cell types have been found with different functions. Neurons form
a complex network, in which they receive, process and transmit information. They
communicate through chemical signals via synapses. The majority of brain cells are
glial cells, which make up 90% in human and 65% in mouse brain (Allen and Bar-
res, 2009). They surround and ensheat neurons for mainting their proper function.
Therefore, glia cells support neurotransmission, maintain ionic balance in the extracel-
lular space and have an active role in information processing (Allen and Barres, 2009).
Nowadays, glia cells are recognised for their importance in the brain (Barres, 2008;
Ja¨kel and Dimou, 2017). They are subdivided into microglia, astrocytes, oligodendro-
cytes, NG2 and ependymal cells.
The following study focuses on the role of microglia and astrocytes in the healthy and
diseased brain.
1.1 Hippocampus
The hippocampus is located in the medial temporal lobe of the brain and belongs to the
limbic system. Each hemisphere contains a hippocampus. The name originates from
its shape, which is formed like a seahorse. It is divided into the dentate gyrus (DG)
and cornu ammonis (CA1-4). The CA consists of densely packed pyramidal neurons,
which somas’ are forming the stratum pyramidale (str. pyr.), whereas their axons extent
into the subiculum towards entorhinal cortex (EC) and the dendrites project into the
11
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Figure 1.1 Neuronal trisynaptic circuit in the hippocampus: The hippocampus receives input
from the entorhinal cortex (EC) via the perforant path to the dentate gyrus. The dentate granule
cells project on CA3 neurons, which transmit information via the Schaffer collaterals to CA1 pyrami-
dal neurons. Their axons signal into the subiculum towards the EC. The small image illustrates the
localization of the hippocampus in the rodent brain. LPP, lateral perforant pathway; MPP, medial
perforant pathway. Source: modified from Deng et al. (2010)
layer called stratum radiatum (str. rad.). Between the str. rad. and DG is the stratum
lacunosum moleculare. The DG contains the granule cells, which form a V-shape layer.
The inner layer is called hilus and includes the subgranular zone, which is one of the
neurogenic niches in the adult brain with the ability to continuously develop neural stem
cells (Seri et al., 2001).
The hippocampus has been well studied for its information transmission from the DG,
CA3 to CA1, which together form a trisynaptic circuit. The DG receives input from the
EC and projects by unmyelinated axons called mossy fibers to CA3 pyramidal neurons.
They (Schaffer collaterals) project on dendrites of CA1 pyramidal neurons in the str.
rad., whose axons signal back to the EC (Fig. 1.1) (Deng et al., 2010; Ramo´n y Cajal,
1909). Due to its neuronal signalling circuit, the hippocampus plays an important role in
learning and memory consolidation. Long-term potentiation and long-term depression
are widely used to study synaptic transmission and plasticity, which is correlated with
memory function (Bliss and Gardner-Medwin, 1973; Hebb, 1949).
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1.1.1 Microglia
Microglia are part of the immune system, born in the yolk sac and enter the brain
from circulating blood (Allen and Barres, 2009). They are involved in synaptic re-
modelling during development and the resident immune cells of the CNS, which scan
the brain for infection or damage (Kreutzberg, 1996; Schafer et al., 2013; Heneka et
al., 2015). Resting microglia have a small cell body with fine and ramified processes.
They patrol the CNS and within minutes reorganise their processes and appear to probe
the neuronal microenvironment (Nimmerjahn et al., 2005; Fetler and Amigorena, 2005;
Garden and Mo¨ller, 2006).
In pathophysiological conditions it is still debated whether microglial cells are harmful
or rather helpful (Allen and Barres, 2009; Wang et al., 2015). During the development
of a disease, microglia shift from a neuroprotective to a classically activated phenotype
(Wang et al., 2015). Neuronal damage (ATP), bacterial products (LPS), pathological
proteins (amyloid beta) and cytokines (TNF-α) can activate microglial cells, which un-
dergo phenotypical transformation into an amoeboid form due to long-term changes of
gene expression (Kreutzberg, 1996; Garden and Mo¨ller, 2006) (Fig. 1.2). This classical
activation phenotype is also called ”M1” (Boche et al., 2013). They display a large
number of receptors on their surface initiating or modulating further immune responses
(Hanisch, 2002). The ”M2” phenotype promotes tissue remodelling and angiogenesis by
releasing antiinflammatory molecules, such as IL-10, IL-4, IL-13 and TGF-β (Wang et
al., 2015). Activated microglial cells are the first ones that respond to injury, pathogens
or other pathophysiological triggers by increasing their cytokine expression and releas-
ing proinflammatory mediators, such as IL-1β and TNF-α to effect neighbouring cells
(Wang et al., 2015). It was shown in a transgenic TNFR dKO mouse model with ischemic
brain injury that TNF-α activated exclusively microglial cells, which in turn produced
neurotoxic substances (Bruce et al., 1996). Therefore, microglia can trigger synergistic
cytokine release with activated astroytes (Pascual et al., 2012). Finally, microglia trans-
form into active phagocytes, cleaning up dead cells and debris (Kettenmann et al., 2013).
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Figure 1.2 Pathomechanistic sequelae of microglia activation: Physiological function of mi-
croglia includes the tissue surveillance and synaptic remodelling. Certain triggers, like persistent ex-
posure to proinflammatory cytokines cause an immune activation, which finally results in chronic neu-
roinflammation. Microglia retract their processes causing functional and structural changes that result
in neuronal degeneration. TLR=Toll-like receptor. Source: modified from Heneka et al. (2015)
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1.1.2 Astrocytes
Astrocytes are the most abundant cells in the mammalian brain and the name originates
from their star-like morphology (Kettenmann and Ransom, 2013; Gonzalez-Perez et al.,
2015). There are two main types: i) protoplasmic and ii) fibrous astrocytes (Ramo´n
y Cajal, 1909). Protoplasmic astrocytes are found in the grey matter and exhibit a
spongiform morphology due to fine radially spread processes. The fibrous astrocytes
are present in the white matter and display longer processes, which provide structural
support for axons. Both types can be identified by the glial fibrillary acidic protein
(GFAP), which is used as a typical astrocyte marker in immunohistochemistry (Nolte et
al., 2001). Protoplasmic astrocytes have fine branched processes, which are in close prox-
imity to synapses. Therefore, they contribute to metabolic and homoeostatic balance in
the brain. Moreover, they contribute to functional integrity of the blood-brain-barrier
(BBB) (Wilhelmsson et al., 2006). Astrocyte endfeet enwrap the walls of blood vessels
tightly (Abbott, 2002). That gives them the chance to actively regulate the diameter of
vasculature and to control the blood flow in the brain (Haydon and Carmignoto, 2006;
Wang and Bordey, 2008). They are able to take up ions, metabolites and water from
the blood. Vice versa this connection is used for the release of toxic substances, clear-
ance of ions and metabolites. Therefore, astrocytes are important for maintaining the
homoeostasis in the brain. To due so, they express many transporters and channels in
their endfeet such as glucose transporters, aquaporins and potassium channels (Wang
and Bordey, 2008).
Astrocytes occupy their own domains, meaning that they contact the neighbouring as-
trocyte in a non-overlapping manner (Pekny et al., 2014; Bushong et al., 2002). They
only overlap each other by 10% of their distal processes (Halassa et al., 2007).
Astrocytes coordinate the transport of glucose from blood vessels to neurons, by convert-
ing glucose into lactate by glycolysis, which neurons demand for their energy supply, e.g.
for generating action potentials (Howarth, 2014; Rouach et al., 2008). This metabolite
conversion is known as astrocyte-neuron lactate shuttle and provides a constant energy
supply (Giaume et al., 2010). Furthermore, during neuronal firing ions and neurotrans-
mitters are spilled over. Those are taken up by astrocytes maintaining the homoeostasis
in the brain (see chapter 1.4.2).
Through gap junction coupling (GJC) astrocytes communicate intercellularly by dis-
tributing molecules with less than 1-1.2 kDa weight and 1.5 nm diameter through their
network (Giaume et al., 2010). Studies investigating in the permeability of gap junction
channels have shown, that the exchange of molecules depends on their weight, structure
and charge, as well as on their specific interactions within the channel pore, such as elec-
trostatic binding forces (Giaume et al., 2010). Via GJC an equal distribution of ions (K+,
Na+), second messenger molecules (IP3, cAMP), water, metabolites (glucose, lactate)
and transmitters is maintained (Wallraff, 2006; Giaume et al., 2010; Bedner et al., 2006;
Niermann et al., 2001; Rouach et al., 2008). Gap junctions are formed by connexins
(Cx), which are transmembrane proteins. They form homo- or heterohexamers, called
15
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connexons, displaying different biophysical properties such as conductance, selectivity,
gating properties and sensitivity to transjunctional voltage. Two connexons from adja-
cent cells form a gap junction channel. Such can be between neurons and between glial
cells in the CNS (Nakase et al., 2003). The two major connexins expressed in astrocytes
are Cx43 and 30. Their expression differs within various regions in the brain (Gosejacob
et al., 2011; Griemsmann et al., 2015). A study has shown that the degree of intercel-
lular coupling is higher in the CA1 region than in the CA3 (D’Ambrosio et al., 1998).
Coupling between hippocampal astrocytes is predominantly (78%) mediated by Cx43
(Gosejacob et al., 2011).
Astrocytes control the extracelllar ion concentration by their ability to take up K+
via their inward-rectifying K+ channels (Kir) and two-pore domain TREK-1/TWIK
channels, which are highly present in the astrocytic membrane mediating the passive
conductance (Wallraff, 2006; Seifert et al., 2009; Hwang et al., 2014). Kir4.1 channels are
responsible for the clearance of excess extracellular K+ spillover during high neuronal
activity. Furthermore, the K+ uptake occurs by the Na+/K+/Cl− cotransporters and
Na+/K+-ATP pumps (Kofuji and Newman, 2010; D’Ambrosio et al., 2002). As astro-
cytes are coupled, it allows them to distribute the uptaken K+ from sites displaying
high extracellur concentrations and redistribute it throuh their network to sites with
low extracellular concentrations. This mechanism works due to the difference in resting
membrane and equilibrium K+ potential resulting in a driving force of K+ influx in astro-
cytes (Orkand, 1986). This role in spatial K+ buffering is essential to keep the balance of
K+ in the brain (Orkand, 1986; Kofuji and Newman, 2010). Studies have demonstrated
that in transgenic double knockout mice for Cx43/Cx30, the potassium buffering was
impaired and caused spontaneous epileptiform events and a reduced threshold for the
generation of epileptic activity (Seifert et al., 2010; Wallraff, 2006).
Furthermore, astrocytes actively take part in the formation of synapses and in modulat-
ing synaptic function through bidirectional communication (Bernardinelli et al., 2014).
In the ”tripartite synapse” astrocyte contribute to synaptic activity by releasing neuron-
activating molecules such as glutamate or γ-aminobutyric acid (GABA), and thereby ei-
ther enhancing or inhibiting the neuronal activity (Araque et al., 2014; Newman, 2003).
Glutamate release is dependent on the increase of intracellular Ca2+ levels (Edwards
and Gibson, 2010). The uptake of glutamate occurs via the excitatory amino acid trans-
porters GLAST and GLT-1, which prevents an accumulation of the neurotransmitter in
the synaptic cleft, resulting in neuronal hyperactivity (Seifert et al., 2010; Chaudhry et
al., 1995). If extracellular glutamate binds to astrocytic metabotropic glutamate recep-
tors (mGluR3/5) the intracelluar astrocytic Ca2+ level rises and calcium waves mediated
by inositol-1,4,5-triphosphate (IP3) propagate through GJC (Giaume and Venance, 1998;
Hatton and Parpura, 2004; Steinha¨user and Seifert, 2012). Another way of calcium wave
propagation, which is thought to be the major determinant mechanism, is via ATP-
mediated P2YR1 activation on neighbouring astrocytes (Tian et al., 2006). Astrocytic
ATP is stored in lysosomes, which are released by calcium-dependent exocytosis (Zhang
et al., 2007; Li et al., 2008). Blocking of these lysosomes prevented the astrocytic release
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of ATP and the spread of calcium waves (Bowser and Khakh, 2007). Thus, astrocytic
calcium signalling is able to synchronise the neuronal network activity, resulting in the
release of gliotransmitters and modulation of synaptic transmission (Sasaki et al., 2014;
Malarkey and Parpura, 2008).
Nowadays, the physiological importance of astrocytes on the neuronal survival, synaptic
transmission and plasticity, as well as controlling the homoeostasis in the brain is highly
acknowleged in research. Therefore, an increasing number of studies try to understand
the role which astrocytes play in neurodegenerative diseases, like epilepsy.
1.2 Epilepsy
Epilepsy is a neurological disorder affecting approximately 65 Million people worldwide.
The brain shows unpredictable occurence of seizures, which are characterised by ab-
normal, excessive or synchronised neuronal activity (Fisher et al., 2005; Goldberg and
Coulter, 2013).
Patients suffer from a decreased quality of their life: the daily routine is restricted by
sudden appearance of seizures, which limits the ability to carry out everyday tasks if
no successful therapy is possible. The International Leage Against Epilepsy (ILAE)
works on standardising classification of epilepsies and reports a refined version with new
terminology and concepts yearly. In their last report from 2017 they classified epilep-
tic seizures based on their site of origin into focal (subdivided into aware or non-aware
seizures, and further ”subgrouped as those with motor and nonmotor signs and symp-
toms at the onset”), generalised (arises and involves the entire brain and is divided into
motor and nonmotor (absence) seizures) or unknown onset (with additional features
including motor, nonmotor or tnoic-clonic spasm and ”a seizure type of unknown onset
may later become classified as either of focal or generalized onset) (Fisher et al., 2017).
Of clinical relevance is also a classification of seizures according to their cause (genetic,
structural/metabolic or unknown) (Shorvon, 2011; Panayiotopoulos, 2012).
Epileptic patients receive at first hand medical treatment with antiepileptic drugs (AEDs),
which mainly target neuronal mechanisms, such as inhibiting voltage-gated sodium chan-
nels (e.g. Phenytoin, Carbamazepine) and/or the calcium channels (e.g. Valproic acid,
Felbamate) or increasing the GABAergic neuromodulation (e.g. Phenobarbital) and
reducing the glutamatergic systems (e.g. Topiramate) additionally. Some AEDs act
through unknown mechanisms or their functionality is not yet fully understood (Lev-
etiracetam, Valproate). Still AEDs have the disadvantage to have an impact on the
CNS in general, leading to cognitive impairment or mood alterations. Beside that, one
third of the patients with treatment still have seizures or even become pharmacore-
sistant. For these intractable patients, a resection of the epileptogenic area can help
to live seizure-free after the operation. Specilists in epilepsy centres need to evaluate
the risks of postoperative neurological deficits or infections (Georgiadis et al., 2013;
Rogawski and Lo¨scher, 2004; White et al., 2007).
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1.2.1 MTLE-HS
In 2010 the ILAE published a classification based on the strucural origins of human
epilepsy neuropathology (Berg et al., 2010). The most common form of epilepsy-related
structural causes is hippocampal sclerosis (HS) or Ammon’s horn sclerosis (AHS), which
is characterised by the loss of neurons in the str. pyr., granule cell dispersion (GCD),
astrogliosis, microvascular proliferation and mossy fiber sprouting (Blu¨mcke et al., 1999;
Thom, 2014). It was shown that most of the epileptic seizures originate in the hippocam-
pus, which is part of the medial temporal lobe (De Lanerolle et al., 2003). Temporal
lobe epilepsy (TLE) is ”characterised by recurrent seizure activity originating within the
temporal lobe” (Hubbard and Binder, 2016). TLE is the most common form of epilepsy
in adults and seizures are medically intractable in about 75% of patients with mesial
TLE (Schmidt and Lo¨scher, 2005) MTLE-HS is classified by the ILAE into type 1 the
”classical HS” displaying severe loss of neurons and gliosis in CA1 and CA4 area and
”atypical HS” showing a predominant neuronal cell loss with gliosis in either CA1 (type
2) or CA4 (type 3) (Thom, 2014; Hubbard and Binder, 2016) (Fig. 1.3).
Figure 1.3 Classification scheme of hippocampal sclerosis in epilepsy: In the pictures, pyra-
midal neurons of hippocampal subfields and subiculum are shown in red, granule cells in blue and
astrocytosis in green. Source: modified from Thom (2014)
The neuronal loss results from seizure activity and is accompanied with loss of glu-
tamatergic neurotransmission or/and excessive changes in Na+ and Ca2+ homoeosta-
sis. Neurons become stressed, resulting in the production and release of free-radical
oxygen species (ROS) accumulating in the cells and causing necrosis (Henshall, 2007;
Dericioglu et al., 2013). Additionally, osmolytic stress activates molecular cell pathways
for apoptosis, a form of p53-driven controlled cell death (Hanahan and Weinberg, 2000).
Moreover, the GCD is typically seen in context of hippocampal neuronal loss and it was
suggested by Thom (2014) that this is an aquired process rather than a pre-existing ab-
normality as it was found in epilepsies with early onset, like febrile seizures occuring in
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infants in long lasting forms of epilepsy (Blu¨mcke et al., 2009). There are two theories,
explaining the occurrence of dispersed neurons: either they are newly generated follow-
ing atypical neurogenesis (Fahrner et al., 2007; Engel et al., 2011) or occur by abnormal
migration of mature neurons, so called ’somatic translocation’ (Murphy and Danzer,
2011). This describes the shift of the cell body into an apical dendrite and was reported
in animal models and resected tissue from epileptic patients with HS, which displayed a
wider branching of dendrites (Murphy and Danzer, 2011; Freiman et al., 2011). Finally,
the reduction or loss of neurons in HS has been associated with impairment of memory
performance in TLE, indicating its importance for epileptic patients (Coras et al., 2010;
Kara´di et al., 2012).
Astrogliosis or reactive gliosis refers to hypertrophic glial cells, which are present in
slerotic but also non-sclerotic human tissue (Das et al., 2012; Binder and Steinha¨user,
2006). Animal models have shown that astrocytes typically display thickened and long
processes in the latent phase and early chronic stage of epileptogenesis. Those hyper-
trophic astrocytes are prominently exhibited in immunohistochemical staining against
GFAP. Beside an upregulation of GFAP high vimentin immunoreactivity is a second pro-
nounced marker of sclerotic hippocampus (Das et al., 2012). In the late chronic phase (9
months after status epilepticus) rather diffuse GFAP staining pattern was found and cell
structures difficult to detect (Bedner et al., 2015). Similarities were found in hippocam-
pal sclerosis from epileptic patients, which also displayed pronounced diffuse GFAP-
immunoreactivity or rather long astrocytic fibrils (Hinterkeuser et al., 2000). Moreover,
co-staining of individual cells with S100β was necessary to clearly identify glial cells
in the hippocampus of AHS specimen (Bedner et al., 2015; Hinterkeuser et al., 2000).
Furthermore, several other glial specific proteins are altered in their expression and used
as ’hallmarks of HS’ (Pekny and Nilsson, 2005; Wilhelmsson, 2004).
1.2.2 Animal models of epilepsy
This chapter shall give a brief overview of animal models of epilepsy. As different
types of epilepsy appear, several animal models are established to study specifically
the underlying mechanism or approaching the distinct type of epilepsy. This project
aimed to investigate TLE in a kainate-induced mouse model.
A perfect model would need to mimick the human situation very closely: i) age of
onset, ii) the seizure phenotype and EEG characteristics and iii) comorbidities and
long-term consequences (Raol and Brooks-Kayal, 2012). Depending on the intention of
investigation, several animal models have been developed following a variety of goals: i)
discovery and characterisation of new AEDs, ii) understanding the relevant processes for
the seizure onset and epileptogenesis and iii) discovery of antiepileptogenic treatments
in chronic models of epilepsy (Hubbard and Binder, 2016; Lo¨scher and Brandt, 2010;
Lo¨scher, 2011). Animal models, which have the purpose to study the development of
epilepsy should depict typical characteristics of epileptogenesis, that includes the initial
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precipitating insult (e.g. SE, traumatic brain injury, febrile seizures), the seizures-free
latent phase and the subsequent period of spontaneous recurrent seizures (SRS) activity.
For induced TLE models the chemoconvulsants kainic acid (KA) or pilocarpine are
applied either systemically into the body or locally into the brain. Both models are used
for understanding the processes in human TLE with HS (Kandratavicius et al., 2014).
In systemically injected models, the animals show bilateral neuronal damage, which even
exceed the limbic structures while human sclerosis in TLE patients is usually confined
to one hippocampus (Jefferys et al., 2016). Despite that, the mortality rate is very high
and difficult to bring in line with the directive 2010/63/EU on the protection of animals
used for scientific purposes and national government regulations nowadays. Therefore,
models with an unilateral local injection have been developed. The three most commonly
models use KA injections into the amygdala, hippocampus and cortex (Mouri et al., 2008;
Li et al., 2012; Araki et al., 2002; Gro¨ticke et al., 2008; Bedner et al., 2015). All
recapitulate the characteristics of HS, such as neurodegeneration, astrogliosis and mossy
fiber sprouting in the ipsilateral KA-injected side and develop chronic epilepsy with
SRS, serving well as models for the human MTLE-HS (Jefferys et al., 2016; Le´vesque
and Avoli, 2013). All models have an artificial trigger, but the aim is that already in the
early phase after epilepsy induction, comparable similarities exist to epileptic patients
and that animal models predict a similar outcome in the chronic phase, closely mimicking
the human pathophysiological situation.
Animal models are still essential to understand the time course of epileptogenesis and for
developing new AEDs as the resected tissue from neurosurgical operation are exclusively
from chronic pharmacoresistant patients and the research lacks ’control of human tissue’
to fully understand the process of the neurological disorder.
1.3 Inflammation
Basically inflammation describes a complex condition of the body to fight foreign patho-
gens. The immune response consists of two types: i) the innate and ii) the adaptive
response. The innate is a fast, non-specific response with the aim to prevent an ini-
tial infection by activating natural killer (NK) cells and the complement cascade that
progresses into an adaptive immune response. This response requires more time as B-
lymphocytes need to be activated. They memorise permanently the pathogen or produce
antibodies tagging the pathogen and activate T-lymphocytes that induce cell death or
help to activate other immune cells. Neuroinflammation in the brain is mainly a lo-
cal response by activated microglial cells, which are the innate immune cells in the
brain, and astrocytes. Both cell types are able to release proinflammatory cytokines
(small proteins balancing the adaptive and innate response) like interleukin-1β (IL-1β)
and tumor necrosis factor alpha (TNF-α) (Clark et al., 2010; Liddelow et al., 2017;
Liddelow and Barres, 2017).
20
Introduction
1.3.1 IL-1β
The superfamily of interleukins belongs to the cytokines, which are released from macro-
phages, lymphocytes and NK cells as a response to a stimulus and bind to their target
receptors on a diversity of cells. IL-1β acts as a mediator in a variety of inflammatory
responses and has its impact on several cascades of (patho-)physiological events. The
immature pro-IL-1β needs to be cleaved in its active form by the interleukin-1 convert-
ing enzyme (ICE), an cysteine-aspartic protease (caspase) and binds to its receptor one
(IL-1R1) (Thornberry et al., 1992). IL-1β has a naturally produced antagonist (IL-1Ra),
which binds to the same receptor (IL-1R1) without inducing the down-stream signalling
cascade of nuclear factor-κ-B (NFκB)- or mitogen-activated protein kinase (MAPK)
pathway, resulting in gene transcriptional changes in the cell nucleus.
In the brain interleukins are expressed at very low or even undetectable concentrations
under physiological conditions. Their expression is often upregulated in pathophysio-
logical cases by a variety of stimuli. The proinflammatory cytokine TNF-α as well as
hypoxia and cellular injury are able to induce an IL-1β mRNA increase within min-
utes and an upregulation of its protein within hours (Allan et al., 2005). An early
increase is often seen in innate immune cells, like monocytes and the macrophage lin-
eage including microglial cells, wherease a subsequent expression occurs in astrocytes
and invading immune cells, which contribute to neuronal damage (Boutin et al., 2003;
Ching et al., 2005). Therefore, decreasing IL-1β signalling is from great therapeutical
interest. A clinically approved IL-1β receptor antagonist called Anakinra (Sobi) is a
drug used to treat rheumatoid arthritis (RA) (Fleischmann et al., 2006).
1.3.2 TNF-α
Tumor necrosis factor α was initially found to be a potent cytokine produced from im-
mune cells to cause necrosis in tumour cell lines. Several years later the large TNF ligand
family was discovered and TNF-α is nowadays controversially discussed as a pleiotropic
cytokine for its role in normal physiology, in pathophysiology like inflammation and/or
autoimmune disease (Tracey and Cerami, 1994; Chu, 2013).
TNF is mainly produced by macrophages, but also synthesised by other cell types in
the CNS, such as lymphocytes, some populations of neurons, microglia and astrocytes
(Lieberman et al., 1989; Clark et al., 2010; Figiel, 2008). TNF-α exists in two biologi-
cally active forms, a transmembrane bound (tmTNF) and a soluble form (solTNF). The
latter is produced by cleavage of the tmTNF form through the TNF-α converting en-
zyme (TACE) (Chu, 2013; Kriegler et al., 1988; Black et al., 1997). The TNF receptor
(TNFR) family has two members, TNFR1 (p55) and TNFR2 (p75). TNFR1 is ex-
pressed in most tissues while TNFR2 is rather found on immune cells like lymphocytes,
endoepithelial cells and microglia (Wajant et al., 2003; Chu, 2013; McCoy and Tansey,
2008). The two TNF ligands can bind to both TNFRs, but TNFR1 is rather activated
by the soluble form, whereas TNFR2 signalling is induced by the transmembrane form
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(Wajant et al., 2003; Grell et al., 1995). Interestingly, only the TNFR1 contains a death
domain, which gets activated after the ligand has bound to its receptor, leading to a
conformation change and internalisation of the receptor (Sedger and McDermott, 2014;
Palladino et al., 2003).
This change induces various downstream signalling factors, like caspase-8 and -3, which
initiate apoptosis. Or necroptosis is induced via activating receptor-interacting serine/
threonine-protein kinases (RIPK1 and RIPK3). Alternatively, the activation of IKKβ-
NFκB pathway and MAPK-pathway occurs leading to gene transcriptional changes in
the nucleus (Fig. 1.4) (Smolen and Steiner, 2003). Several DNA binding sites for the
NFκB have been detected in TNF−α genes located on chromosomes 7 and 17. There-
fore, the TNF-α expression seems to be dependent on the NFκB-pathway and allows
the cytokine to induce its own regulation (Chu, 2013; Philip and Epstein, 1986). Es-
pecially in the brain, TNF-α signalling is not only inducing injury-mediated microglia
and astrocyte activation, it also has an impact on the synaptic plasticity scaling (Tansey
and Wyss-Coray, 2008; Beattie et al., 2002). TNF-α plays a pivotal role depending on
its concentration: at high levels it causes septic shocks, progresses autoimmune diseases
like RA, leukemia or Crohn’s disease and is a hallmark of neurodegenerative condi-
tions, e.g. Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS),
whereas low TNF-α concentrations may cause cachexia (Wajant et al., 2003; Chu, 2013;
McCoy and Tansey, 2008). It is considered to be one of the major proinflammatory me-
diators, with the capacity to induce cell death via apoptosis or necrosis, and a promising
target for therapeutical approaches.
TNF-α signalling can be inhibited via its i) receptors (Etanercept, Lenercept), ii) lig-
ands (Infliximab, XPro1595), iii) converting enzymes like TACE (GW333, Apratas-
tat) or iv) other pathways, such as inactivating the downstream signalling cascade of
p38 MAPK-pathway (VX-702, RWJ67657) (Fig. 1.5) (Palladino et al., 2003; McCoy
and Tansey, 2008; Kontermann et al., 2009). As the ligands can bind to both TN-
FRs, inducing via TNFR1 cell death but via TNFR2 cell survival, it is important that
next-generation therapeutics target specifically the solTNF-α/TNFR1 signalling path-
way and spares the tmTNF/TNFR2 cascade (Probert, 2015; Marchetti et al., 2004).
Therefore, two new inhibitor strategies have been developed within the last 10 years:
i) exclusive inhibition of the solTNF-α form, e.g. through XPro1595, XENP345 and
ii) selective binding to a TNFR1-domain, e.g. with DMS5540, TROS (Fischer et al.,
2015). Selective solTNF-α inhibitors have a dominant-negative structure (dnTNF),
which allows them to form inactive heterotrimers without inducing the TNFR1 sig-
nalling cascade, thus leaving tmTNF unaffected (Fischer et al., 2015). One example of a
dnTNF inhibitor is the afore mentioned XPro1595 (Xencor) (Steed et al., 2003), which
inhibits the downstream signalling via NFκB pathway (Wajant and Scheurich, 2011;
Fischer et al., 2015). XPro1595 has been used so far in animal models of neurodegener-
ative diseases investigating the role of solTNFα in spinal cord injury (SCI) (Novrup et
al., 2014), AD (MacPherson et al., 2017), PD (Barnum et al., 2014), HD (Hsiao et al.,
2014), MS (Karamita et al., 2017) and limbic epilepsy (Patel et al., 2017) (chapter 6.4).
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Figure 1.4 Simplified overview of TNF-α and IL-1β signalling pathway: Two major path-
ways, the NFκB (left) and the MAPK pathway (right) are activated by the proinflammatory cytokines
TNF-α and IL-1β. (a) The ligation of receptors with proinflammatory cytokines activates the IκB
kinase (IKK) complex, which phosphorylates the NFκB proteins (IκB), leading to their degradation.
Thereby, NFκB enters the nucleus and activates several genes coding for molecules, such as cytokines,
chemokines, cyclooxygenase-2, antiapoptotic and stress proteins. (b) After receptor ligation activates
upstream kinases of MAPKs pathway, the transcription factor AP-1 induces activation of genes coding
for various cytokines, including TNF-α and IL-1β themselves, and other molecules. Proinflammatory
cytokines mostly induce the JNK and p38 MAPK cascades. AP-1, activator protein-1; IRAK, IL-1
receptor-associated kinase; MyD88, myeloid differentiation protein 88; NEMO, NFκB essential modula-
tor; TRADD, TNF receptor-associated death domain protein; TRAF, TNF receptor-associated factor.
Source: modified from Smolen and Steiner (2003)
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Figure 1.5 Strategies to interfere with TNFR action: Anti-TNF antibodies (Infliximab, Adali-
mumab, Certolizumab pegol) and soluble TNFRs (Etanercept, Lenercept) act on both TNF-α forms.
Current solTNF-α/TNFR1 targeting agents under development are selective solTNF-α inhibitors (TNF
muteins) (XPro1595, XENP345) and selective anti-TNFR1 antibodies (DMS5540, TROS, ATROSAB,
R1antTNF). Abbr. tmTNF, transmembrane TNF; solTNF, soluble TNF; TACE, TNF-α converting
enzyme Source: modified from Kontermann et al. (2009) and Fischer et al. (2015)
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1.4 Inflammation in TLE
Until today, the molecular mechanisms underlying TLE are still not fully understood.
Several morphological and functional changes occur within the disease progression in
neuronal and glial cells.
Most prominent are the alterations in astrocytes and microglia, which transform into
an activated pathological state, called gliosis. Gliosis is found in human epileptic brain
(McKhann et al., 2000). Tissue, resected from TLE patients, showed massive gliosis,
characterised by hyperthrophic astrocytes. Several studies found alterations in receptor
expression (mGluR5, P2YR1, IL-1R) and transporter functionality (GLT-1), dysfunc-
tion in BBB, impaired K+ and water homoeostasis, altered Ca2+ transients, release of
gliotransmitters and cytokines (Fig. 1.6).
Furthermore, microgliosis has been found in patients with recurrent seizures as well as
in the hippocampus in experimental models of epilepsy (Beach et al., 1995; Drage et
al., 2002; Van Vliet et al., 2012). Studies showed that activated microglia were present
in patients with intractable MTLE-HS (Beach et al., 1995; Zattoni et al., 2011) and
in close proximity of regions with neuronal loss (Borges et al., 2006). Therefore, some
authors suggest that microgliosis faciliates neuronal malfunction (Beach et al., 1995;
Taniwaki et al., 1996). The author Mirrione et al., observed that KA-induced exci-
totoxicity caused neuronal tissue-type plasminogen activator (tPA) release (Mirrione
et al., 2007). TPA activates microglial cells, which in turn are able to release tPA
and provoke further neuronal injury (Siao et al., 2003). Thus, microglial cells facilitate
seizure recruitment and the chronic maintenance of convulsions (Buckmaster et al., 2002;
Winokur et al., 2004).
It is well known, that activated microglia also express GLT-1 and contribute 10% to
glutamate uptake, while astrocytic GLT-1 is downregulated (Nakajima et al., 2001;
Shaked et al., 2005; Persson et al., 2006). As microglia are the main innate im-
mune cells in the brain, their proinflammatory role is ”postulated to be the etiologic
driver of epileptogenesis” (Zhao et al., 2018; Abraham et al., 2012; Aronica et al., 2017;
Colonna and Butovsky, 2017).
The impact of inflammation on the development of epilepsy is undeniable. In human
and experimental febrile seizure and TLE, increased levels of cytokines were found. A
study by French et al. reported that around 40% of MTLE-HS patients experienced
febrile seizures in their childhood (French et al., 1993). Therefore, inflammation seems
to play an important role as a trigger in the development of TLE, more than just being
a consequence. (Choy et al., 2014; Vezzani et al., 2008; Khan et al., 2016).
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Figure 1.6 Dysfunction of astrocytes in epilepsy: (1) Extracellular elevated K+ due to seizure activity is taken up by Kir4.1
channels, which are downregulated in human and experimental epilepsy. (2) Gap junctional coupling mediates the redistribution of ions
and metabolites. Transgenic knockout animals displayed an impaired K+ buffering. (3) Dislocation of water aquaporin4 channels leads to
impaired potassium buffering and astrocyte cell swelling. (4) Via glutamate transporters (EAAT1 and EAAT2) astrocytes take up glutamate.
In human epileptic hippocampus both transporters were found to be reduced, leading to decreased threshold for seizure induction. (5)
The glutamine synthethase (GS) converts glutamate into glutamine. Hippocampus tissue from epilepsy patients releaved a loss of GS,
causing increased extracellular glutamate levels. A downregulation of GS was also found in experimental epilepsy in the chronic period. (6)
Extracellular glutamate binds to metabotrobic glutamate receptors resulting in intracellular release of Ca2+ and calcium wave propagation
within the coupled astrocytes, resulting in astrocytic glutamate release and neuronal synchronisation. In human and experimental epilepsy
mGluR5 levels have been found to be upregulated. (7) Pro-inflammatory cytokines IL-1β and TNF-α inhibit glutamate uptake and lead to
astrocytic glutamate release, contributing to neuronal hyperexcitability. TNF-α released from astrocytes during epileptogenesis might boost
neuroexcitotoxicity and neuronal death. (8) IL-1β and TNF-α decrease Cx43-mediated GJC, due to phosphorylation of Cx43 C-terminus.
Source: modified from Seifert et al. (2010)
26
Introduction
1.4.1 Proinflammatory cytokines IL-1β and TNF-α in human and
experimental TLE
Several studies have investigated the role of inflammation in epileptogenesis. Especially
the results from experimental models differ slightly, which might be due to the study
design: ”different ages of mice used in the studies, the diverse times chosen to observe
the results and the distinct doses” and ways of inducing epilepsy (Lu et al., 2008).
Hence, the following chapter will mainly focus on alterations of the proinflammatory cy-
tokines IL-1β and TNF-α and their signalling in human and KA-induced experimental
models of TLE.
Data obtained from neurosurgically resected specimen from patients with intractable
TLE, show various neuroinflammatory changes: activated astrocytes and microglial cells
exhibit increased proinflammatory cytokine levels, such as IL-1β and TNF-α (Bordey
and Sontheimer, 1998; Hufnagel et al., 2003; Ravizza et al., 2008; Balosso et al., 2013;
Ashhab et al., 2013). Moreover, parenchymal and perivascular astrocytes display an
upregulation of the TNFR1 signalling pathway (Yamamoto et al., 2006; Balosso et al.,
2013) and a study by Crespel et al. (2002) describes NFκB expression in reactive as-
trocytes, but not in microglial cells, in patients with febrile seizures in early childhood
(Crespel et al., 2002). Additionally, a compromised BBB was found to be contributing
to seizure activity (Dedeurwaerdere et al., 2012; Weinberg et al., 2013).
Several studies investigated the question how TNF-α and its receptors contribute to the
development of seizure activity. The TNF-α/TNFR1 signalling pathway is suggested
to have a proconvulsive role, whereas the TNF-α/TNFR2 signalling rather mediates
anticonvulsive effects (Balosso et al., 2005; Weinberg et al., 2013). These results are
from studies on transgenic TNFR-KO animals with KA-induced SE and overexpres-
sion of TNF-α via injection or viral transfection in wildtype and KA-injected rodents.
Furthermore, the same studies show that the TNFR1 expression is first upregulated in
pyramidal neurons (1 day post SE) and subsequently in astrocytes (1-2 days post SE).
Neuronal TNFR2 expression was decreased and not detectable in astrocytes. An up-
regulation of TNFR1 in astrocytes in mice with intranasal application of KA showed
an induction of astrogliosis (Lu et al., 2008). Another study by Probert et al. (1997)
found that overexpression of TNF-α in naive animals induced astrogliosis. Moreover,
these authors found that these reactive astrocytes were able to produce TNF-α, which
was shown to alter the BBB. Overexpression of TNF-α also mediated microgliosis in
naive and KA-injected animals (Probert et al., 1997; Zhu et al., 2010). Activated mi-
croglia have been shown to express TNF-α 24 hrs after SE induction (Vinet et al., 2016;
Zheng et al., 2009). The TNF-α production and release by activated glia cell has been
shown to induce neuronal injury (Rizzi et al., 2003). Damaged neurons also contribute
to the overexpression of TNF-α, which results in seizures and early mortality (Balosso
et al., 2013; Probert et al., 1997).
Primary hippocampal damage within the first day after SE induction is a directly KA-
induced neuronal death. Whereas, the neuronal cell death, which is observed after that
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time point, is indirectly mediated by the hyperactivity and its induced activation of
enzymatic and nuclear mechanisms (Doble, 1999). The SE-induced neuronal death be-
yond the acute phase was also seen after intraamygaloid injection of KA in rats, which
was caspase-3 mediated (Zhu et al., 2010). Caspase-3 activation occurs via the TNFR1
death domain signalling pathway resulting in apoptosis. Another study in microglia
specific IKK-KO mice found that the KA-induced neuronal death was decreased, sug-
gesting that dead neurons release microglia activational factors, such as high mobility
group box-1 (HMGB1) (Cho et al., 2008; Dedeurwaerdere et al., 2012). Indeed, Cho
et al. (2008) observed less activated microglial cells and astrocytes in the transgenic
animals, indicating that the activation of microglia precedes that of astrocytes. The
IKK-NFκB pathway is also activated by the IL-1β/IL-1R1 signalling. IL-1β is pro-
duced by astrocytes during the acute and chronic phase after SE induction, while in
microglial cells IL-1β production was only present in the acute phase (Rizzi et al., 2003;
Vezzani et al., 2002; Ravizza et al., 2008). IL-1R1 expression was found to be upreg-
ulated in hippocampal neurons and astrocytes in the acute phase, and decreased in
astrocytes in the chronic phase after SE induction (Vezzani et al., 2002; Ravizza et al.,
2008). In microglial cells IL-1R1 was not expressed (Vezzani et al., 2002; Ravizza et
al., 2008). Overexpression of IL-1β is able to induce TNF-α production in astrocytes
and microglial cells in naive animals via the IKK-NFκB pathway (Vezzani et al., 2002;
O’Neill and Bowie, 2007) (Fig. 1.4).
Microglia are the ”upstream partners” of astrocytes and are the first cells releasing
inflammatory mediators, like TNF-α, triggering the activation of astrocytes (Lund et
al., 2006; Pascual et al., 2012; Wang et al., 2015). Activated astrocytes synergise with
microglia to release TNF-α (Garden and Mo¨ller, 2006; Bezzi et al., 2001), which attenu-
ates together with IL-1β the glutamate uptake by astrocytes (Ye and Sontheimer, 1996;
Hu et al., 2000). Furthermore, glial release of TNF-α induces Ca2+ increase via binding
to P2YR1 and elevated extracellular glutamate levels (Vezzani et al., 2011; Santello et
al., 2011). High extracellular glutamate levels contribute to seizure generation by hy-
peractivation of AMPAR and NMDAR on the postsynaptic neuron (Beattie et al., 2002;
Stellwagen and Malenka, 2006; Viviani et al., 2003). A third observation found in in
situ, in vitro and in vivo studies is that both proinflammatory cytokines inhibit the
astrocytic GJC, which is known to result in extracellular accumulation of K+ and glu-
tamate (Meˆme et al., 2006; Bedner et al., 2015).
In summary, different proinflammatory cytokines have been shown to exert various ef-
fects, depending on the type of receptor expression in the brain tissue and the inflam-
matory trigger. Still, most studies favour proconvulsive role of TNF-α and IL-1β in the
development of TLE.
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1.4.2 Role of astroglial coupling in TLE
The role of astroglial GJC in the development of TLE is still debated, as it has anti- as
well as proconvulsive effects on epileptogenesis.
The astrocytic GJC has an anticonvulsive role in clearing neurotoxic substances, such
as high levels of K+ and glutamate.
During neuronal activity extracellular K+ concentration increases. To keep the K+ bal-
ance in the brain, astrocytes take it up through the Kir4.1 channels and distribute it via
their GJC (spatial buffering). Therefore, the astrocytic GJC preserves the potassium
homoeostasis even during neuronal hyperactivity, which occurs during seizure activity
(Wallraff, 2006). Furthermore, glutamate released into the synaptic cleft during neu-
ronal activity is taken up by astrocytes mainly via GLT-1 and transport it within the
network to astrocytes displaying lower glutamate concentration.
A study from Pannasch et al. (2011) using the transgenic mice devoid of the astro-
cytic proteins Cx43 and Cx30, in which the astrocytic GJC is completely lost, found
decreased glutamate clearance causing alterations in synaptic transmission. Such a dis-
turbance can cause enhanced neuronal susceptibility to hypersynchronisation resulting
in neuroexcitotoxicity, which is typically seen in epilepsy (Meldrum, 1994; Coulter and
Steinhauser, 2015).
Other studies in transgenic dKO mice for Cx43 and Cx30 revealed the importance of as-
trocytic GJC for the K+ clearance. The mouse line Cx30−/−; Cx43fl/flhGFAP-Cre lacks
both connexins and therefore lacks astrocytic GJC. In these mice the spatial buffering
exhibited epileptiform events (Wallraff, 2006). A recent study from Bedner et al. (2015)
investigated the role of astrocytic K+ spatial buffering in the SE-induced KA model of
TLE in vivo. Four hours post KA injection, the GJC was already found to be reduced
by 50% and the K+ clearance was impaired.
In conclusion, the astrocytic GJC manages the redistribution of K+ and glutamate
accumulation from sites of high neuronal activity to avoid their accumulation in the
extracellular space and the consequential seizure activity (Pannasch et al., 2011; Bedner
et al., 2015). As the reduction in the astrocytic coupling appeared even before neuronal
death at an early time point, Bedner et al. (2015) suggested that the astrocytic uncou-
pling causes the development of TLE.
Other studies claim a proconvulsive role of astrocytic GJC in epilepsy. Through the as-
trocytic GJC glucose and lactacte can be transported to supply neurons, which demand
energy for generating epileptiform activity (Rouach et al., 2008; Giaume et al., 2010).
The delivery of metabolites for neurons via the GJC is more efficient than free extra-
cellular diffusion of glucose, and covers a longer distance (Rouach et al., 2008). More-
over, there is some evidence that glutamate binds to astrocytic mGluR1/5 and con-
tributes to calcium wave propagation within the coupled astrocytes (Ding et al., 2007;
Seifert et al., 2010). That causes glutamate release from astrocytes contributing to
the modulation of synaptic transmission and to non-synaptic neuronal synchronisation
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(Ding et al., 2007). It was shown that high levels of glutamate are not only able to in-
duce seizures, but also cause neuronal loss in epilepsy (Meldrum, 1994; Chapman, 1998).
Whether the astrocytic GJC plays an anti- or proconvulsive role depends on the specific
experimental condition.
In conclusion, a reduction of GJC leads to neuronal hyperactivity as K+ and gluta-
mate cannot be redistributed via the network. Neurons need subsequent delivery of
metabolites for ongoing activity, which is hardly affordable in cases of reduced GJC.
Furthermore reduced propagation of calcium waves are possible in cases of decreased
GJC, and therefore neuronal synchronised firing would not occur.
An increase of GJC contributes to an equal distribution of K+ and glutamate, prevent-
ing neuronal hyperexcitability. Still via calcium waves glutamate release is triggering
neuronal firing, which is sustained by metabolic supply via the increased astrocytic GJC.
Taken together, the increase or decrease of GJC in the astrocytic network plays an im-
portant role in the neuronal supply and maintainance of homoeostasis in the brain.
Studies, investigating the changes of Cx43 expression levels of mRNA or protein re-
vealed controversial results. Often an increase of expression was found in animal models
of experimental epilepsy (Takahashi et al., 2010; Szente et al., 2002). Also in cell culture
elevated Cx43 protein levels were seen after KA-induced SE (Samoilova et al., 2003),
suggesting that an upregulation of Cx43 compensates the elevated K+ levels during
epileptiform activity (Seifert et al., 2010). In contrast, in in vivo models of epilepsy no
significant changes of the mRNA levels of Cx43 were found in epileptic hippocampus
(Khurgel and Ivy, 1996; So¨hl et al., 2000; Samoilova et al., 2003). Other studies found a
downregulation of Cx43 mRNA (Elisevich et al., 1997; Elisevich et al., 1998) and protein
level and GJC in a mouse model of tuberous sclerosis (Xu et al., 2009).
These controversial results may derive from the differences of the used animal models of
epilepsy, such as study design, the examined time point and choice of animals.
Study results from human epileptic tissue are contentious. Hippocampal tissue resected
from patients with MTLE displayed an increase of Cx43 protein level (Fonseca et al.,
2002; Collignon et al., 2006). In line with that are the studies of Naus et al., Aron-
ica et al. and Desphande et al., which found elevated levels of Cx43 in pharmacore-
sistant (tumour-associated) epilepsy patients (Naus et al., 1991; Aronica et al., 2001;
Deshpande et al., 2017).
Furthermore, Steinha¨user et al. suggested that alterations of mRNA and protein lev-
els of Cx43 do not give direct information of the functional GJC of astrocytes in TLE
(Steinha¨user et al., 2012). The function of gap junctions are regulated by posttransla-
tional modifications like kinase-induced phosphorylation, which influences the assembly
of connexons, open probability and their location and GJ gating properties.
Therefore, our group has investigated recently the subcellular localisation of Cx43 in tis-
sue obtained from MTLE-HS patients and experimental TLE (Deshpande et al., 2017).
This study revealed a redistribution of Cx43 protein towards perivascular endfeet in HS.
Furthermore, the authors suggest that rather increased phosphorylation at serine 255
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at the C-terminus of Cx43 might contribute to the astrocytic uncoupling in MTLE-HS,
than reduced connexin expression.
To identify the mechanism causing the SE-induced early loss of astrocytic GJC, which
has been shown to crucially contribute to the cause of TLE, Deshpande et al. (2018)
investigated the Cx43 expressional changes and phosphorylation status in KA-induced
epilepsy mouse model (Deshpande et al., 2018). Four hours after SE induction, the
authors found an increase of phosphorylation at the serine 262 (S262) position of the
C-terminus of Cx43, but no changes in the Cx43 expression. S262 is phosphorylated by
MAPKs, resulting in decreased open probability and a rapid internalisation of Cx43 GJ
channels (Lampe et al., 1998; Thevenin et al., 2013). As lately, Bedner et al. (2015)
found a significant reduction of astrocytic GJC also 4 hrs after KA-induced SE and
showed that proinflammatory cytokines, like IL-1β and TNF-α, significantly decreased
the astrocytic GJC in control tissue, Deshpande et al. (2018) inhibited the solTNF-α
by applying the antagonist XPro1595. In this study, the authors found no astrocytic
uncoupling in situ and demonstrated that by the inhibition of solTNF-α the phosphory-
lation of S262 was prevented. These results assume that the release of proinflammatory
cytokines contributes to astrocytic GJC alteration in the early development of TLE.
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2 Aim of the Study
About one third of epilepsy patients do not adequately respond to available antiepileptic
drugs, which merely suppress seizures without curing the underlying disorder. Conse-
quentially, new strategies for the development of disease-modifying or antiepileptogenic
drugs are urgently needed. There is indeed growing evidence that brain inflammation
is not only a consequence but often a causal event in epilepsy (Vezzani et al., 2011).
The present study aimed at understanding the contribution of inflammation-induced
astrocyte malfunction in the development of TLE. This gave me the intention to focus
on the following questions:
(i) Are proinflammatory cytokine levels altered and do they have an impact on astrocytic
gap junction coupling within the development of TLE?
Astrocytic gap junction coupling is reduced by 50% four hours after SE and completely
lost after three months (Bedner et al., 2015). As cytokines mediate this alteration
(Meˆme et al., 2006; Bedner et al., 2015), that part of the study aimed at characterising
the cytokine expression levels within the first day after SE. To better understand the
contribution of gap junction coupling in the progression of TLE, it was a goal to further
characterise the coupling strength in the latent and chronic phase.
(ii) Does inhibition of soluble TNF-α rescue astrocytic gap junction coupling?
The application of XPro1595 in situ, a specific inhibitor of soluble TNF-α, restored
the proinflammatory cytokine-mediated astrocytic uncoupling in acute brain slices in
wildtype animals (Desphande et al., 2018). The aim of this part of the study was to
assess whether XPro1595 administrations before and after SE influences seizure-induced
astrocytic uncoupling in the intracortical model of TLE. The results would provide an
important basis to understand the function of solTNF-α/TNFR1 signalling in epilepsy.
(iii) Does inhibition of soluble TNF-α suppress the development of chronic seizures and
hippocampal sclerosis?
The application of antiinflammatory drugs has been shown to decrease seizure activity
(Ravizza and Vezzani, 2006; Libbey et al., 2011). The present study focused on the
specific inhibition of solTNF-α/TNFR1 casacade as it is reported to have a proconvul-
sive role in the development of epilepsy (Balosso et al., 2005; Weinberg et al., 2013).
The goal was to examine if XPro1595 attenuates the histopathological changes and re-
duces epileptic seizure activity, if applied before SE, in the acute phase or after the first
spontaneous generalised convulsive seizure.
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3 Materials
3.1 Chemicals
Compound Company
Anakinra Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden
Antisedan R© Orion Pharma, Espoo, Finland
Aquapolymount Polysciences, Warrington, USA
Bepanthen R© Bayer, Leverkusen, Germany
Baytril 2.5% Bayer, Leverkusen, Germany
Betaisodona R© Mundipharma GmbH, Limburg, Germany
Biocytin Sigma-Aldrich, Mu¨nchen, Germany
CaCl2.6H2O AppliChem GmbH, Darmstadt, Germany
Carbogen Linde, Pullach, Germany
Cepetor CP-Pharma, Burgdorf, Germany
Ethanol 99% AppliChem GmbH, Darmstadt, Germany
Glucose AppliChem GmbH, Darmstadt, Germany
Hoechst 33342 Molecular Probes, Eugene, USA
Isofluran Piramal Healthcare, Morpeth, UK
Kainic acid Tocris, Bristol, UK
Ketamin R© 10% WDT, Garbsen, Germany
Lipopolysachharide Sigma-Aldrich, Mu¨nchen, Germany
MgSO4.7H2O AppliChem GmbH, Darmstadt, Germany
Na-Azide Sigma-Aldrich, Mu¨nchen, Germany
NaCl AppliChem GmbH, Darmstadt, Germany
NaDOC AppliChem GmbH, Darmstadt, Germany
NaH2POH4 AppliChem GmbH, Darmstadt, Germany
NaHCO3 AppliChem GmbH, Darmstadt, Germany
NP-40 AppliChem GmbH, Darmstadt, Germany
Pala clear Paladur, Hanau, Germany
Paraformaldehyde AppliChem GmbH, Darmstadt, Germany
Rimadyl R© Pfizer, New York, USA
SDS AppliChem GmbH, Darmstadt, Germany
Sodium pyruvate AppliChem GmbH, Darmstadt, Germany
SR101 Sigma-Aldrich, Mu¨nchen, Germany
Streptavidin-Cy3 Sigma-Aldrich, Mu¨nchen, Germany
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Sucrose AppliChem GmbH, Darmstadt, Germany
Surgical PGA and Polyester Smi, St. Vith, Belgium
Tris AppliChem GmbH, Darmstadt, Germany
TritonX-100 Sigma-Aldrich, Mu¨nchen, Germany
Tween-20 AppliChem GmbH, Darmstadt, Germany
XPro1595 Xencor, Monrovia, USA
Xylazine hydrochloride Sigma-Aldrich, Mu¨nchen, Germany
3.2 Software
Programme name Company
Dataquest A.R.T 4.00 Gold/Platinum DSI, St. Paul, USA
Igor Pro Wave Metrics, Portland, USA
ImageJ NIH, Maryland, USA
Imaris 8.0 Bitplane, Belfast, UK
LAS AF Leica Microsystems, Wetzlar, Germany
SeeTec Office 5 SeeTec, Philippsburg, Germany
Tida Heka, Lambrecht, Germany
3.3 Devices and equipment
Device Company
Axioskop Zeiss, Jena, Germany
centrifuges Eppendorf, Wesseling, Germany
DMZ Zeitz-Puller Zeitz, Martinsried, Germany
EPC-9 Heka, Lambrecht, Germany
fluorescence lamp HBO100 Zeiss, Jena, Germany
heating plate FMI, Beerbach, Germany
Leica SP8 LSM Leica Microsystems, Wetzlar, Germany
Infinite M200Pro Tecan, Ma¨nnedorf, Switzerland
IR camera Axis 221 Axis Communications AB, Lund, Schweden
IPC pump Ismatec, Wertheim, Germany
micromanipulator MHW-3 Narishige, Tokyo, Japan
microsyringe Hamilton, Bonaduz, Switzerland
PCO (camera setup) CCD Imaging, Kehlheim, Germany
perfusor Braun, Melsungen, Germany
pH meter Mettler Toledo, Giessen, Germany
Precellys24 Bertin Technologies, Montigny-le-Bretonneux, France
QuickPlex SQ120 MSD, Maryland, USA
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radio receiving plate DSI, St. Paul, USA
stereotactic frame TSE Systems GmbH, Bad Homburg, Germany
syringe pump SP220IZ WPI, Sarasota, USA
table top small centrifuge VWR, Darmstadt, Germany
Vibratome VT1200S Leica, Nussloch, Germany
vortexer VWR, Darmstadt, Germany
V-Plex Kit 15048D MSD, Maryland, USA
weight balance Sartorius group, Go¨ttingen, Germany
3.4 Antibodies
Primary Antibodies
Epitope Species Type Dilution Company
GFAP mouse mc 1:500 Abcam
GFAP rabbit pc 1:500 Dako
NeuN mouse mc 1:300 Chemicon
S100b mouse mc 1:500 Sigma
S100b rabbit pc 1:500 Abcam
TNFR1 rabbit pc 1:1000 Abcam
Secondary Antibodies
Antibody Species Dilution Company
anti-mouse-A488 goat 1:500 Molecular Probes
anti-rabbit-A488 goat 1:500 Molecular Probes
anti-mouse-A647 goat 1:500 Molecular Probes
anti-rabbit-A647 goat 1:500 Molecular Probes
Streptavidine Conjugates
Streptavidin-Cy3 1:300
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3.5 Solutions and buffers
3.5.1 Solutions for electrophysiology
Preparation solution
NaCl 87 mM
KCl 2.5 mM
NaH2PO4 1.25 mM
NaHCO3 25 mM
MgSO4.7H2O 7 mM
CaCl2.6H2O 0.5 mM
Glucose 25 mM
Sucrose 75 mM
pH 7.35-7.4 at 24◦C adjusted with carbogen (95% CO2 and 5% O2.)
Osmolarity 320-330 mosmol
Artificial cerebrospinal fluid (ACSF)
NaH2PO4 1.25 mM
NaCl 126 mM
KCl 3 mM
MgSO4.7H2O 2 mM
CaCl2.6H2O 2 mM
Glucose 10 mM
NaHCO3 26 mM
pH 7.35-7.4 at 24◦C adjusted with carbogen (95% CO2 and 5% O2.)
Osmolarity 305-315 mosmol
Intracellular K-gluconate solution
K-gluconate 130 mM
MgCl2.6H2O 1 mM
Na2-ATP 3 mM
EGTA 10 mM
HEPES 20 mM
pH 7.2 at 4◦C, Osmolarity 280-285 mosmol
supplemented with 0.5% biocytin
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3.5.2 Solutions and buffers for immunohistochemistry
Phosphate buffered saline (PBS 10x)
NaCl 1.5 mM
Na2HPO4 83 mM
NaH2PO4 17 mM
dissolved in dH2O, pH 7.4
PBS with sodium azide
NaN3 0.01% (w/v) dissolved in 1x PBS
Paraformaldehyde solution
Paraformaldehyde 4% (w/v) dissolved in PBS and dH2O, pH 7.4
Blocking solution
NGS 10% (v/v)
TritonX-100 0.5-2% (v/v)
diluted in 1x PBS, pH 7.4
1st antibody solution
NGS 2-5% (v/v)
TritonX-100 0.1-1% (v/v)
diluted in 1x PBS, pH 7.4
2nd antibody solution
NGS 2% (v/v)
TritonX-100 0.1% (v/v)
diluted in 1x PBS, pH 7.4
Hoechst nuclei staining solution
Hoechst 0.5% (v/v)
diluted in dH2O
3.5.3 Solutions and buffers for ELISA
Phosphate buffered saline (10x)
NaCl 8000 mg/l
KCl 200 mg/l
Na2HPO4 1150 mg/l
KH2PO4 200 mg/l
MgCl26H2O 100 mg/l
CaCl2 100 mg/l
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dissolved in dH2O, pH 7.4
Homogeneity solution Complete Protease Inhibitor, Roche 1 tablet
dissolved in 25 ml dH2O
RIPA solution (2x)
Tris 50 mM
NaCl 150 mM
NP-40 2 %
NaDOC 1 %
SDS 0.2 %
dissolved in dH2O
3.6 Animals
Animals used in this project were handled on the directive 2010/63/EU on the protec-
tion of animals used for scientific purposes and national government regulations. All
experiments were designed and realised to minimise the number of animals due to the
”Three Rs” presented in the directive 2010/63/EU. The animals were facilitated in the
”Haus fu¨r Experimentelle Therapie” (HET) under standard housing conditions with a
12 / 12 hrs dark-light cycle. Employed keepers ensured the availability of food and
drinking water during the whole time. For the project male transgenic mice with either
FVB (Friend leukemia virus B) or C57BL/6 background were used.
3.6.1 hGFAP-eGFP mice
This transgenic mouse line with FVB background has an endogenous green flourescent
protein (eGFP) expressed under the human glial fibrillary acidic promotor (hGFAP). A
fragment of the hGFAP promotor was injected into a multiple cloning site into FVB/N
oocytes (Nolte et al., 2001). In those animals mainly astrocytes are labbeled in green
in the whole brain, including the hippocampus (Nolte et al., 2001). Additionally eGFP
expression is found in NG2 cells (Wallraff et al., 2004). Male mice aged p90 to p120
were used for whole-cell patch-clamp recordings, stainings and molecular approaches like
ELISA.
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3.6.2 TNFR1 KO mice
The TNFR1 knockout animals or homozygous p55 lacking mice were originally ordered
from Jackson Laboratory, ordering number 003242 known as Tnfrsf1a tm1/mx and were
a gift from Zeinab Abdullah. They are C57BL/6 inbred. This transgenic mouse line is
useful for investigating the role of TNFR1 signalling in different biological responses, such
as TNFR1 contribution in neuroinflammatory-induced diseases. Mice aged p90 to p120
were used for whole-cell patch-clamp experiments, stainings and molecular approaches.
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4 Methods
4.1 Electrophysiology
4.1.1 Preparation of acute brain slices
For the preparation of acute brain slices animals were deeply anaesthetised with isoflu-
rane and decapitated. After the quick removal of the brain, coronal brain sections of
200 µm were cut for whole-cell patch-clamp experiments at a vibratome (VT1200S, Le-
ica) with the speed of 0.08-0.12 mm/s and an amplitude of 1-1.2 mm. During cutting,
the brain was placed in ice-cold preparation solution, which was constantly gased with
carbogen (95% oxygen and 5% carbogen). To distinguish between the left (non-epileptic
hemisphere) and right (ipsilateral) a little cut was made at the bottom on the left hemi-
sphere. Sections only around the KA injection spot were used for the recordings. After
cutting 5 slices, they were placed into 35◦C warm and carbogenised sucrose to let them
recover for 20 min. To better visualise the hippocampal astrocytes in adult mice brain,
all sections were stained with 1 µM sulforhodamin 101 (SR101) in carbogenised ACSF
at 35◦C for additional 20 min (modified protocol from Schnell et al. (2012)). Finally, the
sections were placed into a beaker with ACSF at room temperature (RT) for patch-clamp
recordings. The compounds of all solutions are described in chapter 3.5.1.
4.1.2 Electrophysiological setup
Whole-cell patch-clamp recordings of astrocytes were obtained at an electrophysiological
setup placed in a Faraday cage and balanced on a vibration isolated table (Newport) to
sustain stationary recordings. Brain sections were cut into half and one of them placed
in a bath chamber, which is perfused with carbogenised ACSF continously by a peri-
staltic pump (speed 1 ml/min). To keep the tissue at its place, it was placed under a
U-shaped platinum wire with nylon strings glued on it. Patch-clamp electrodes made
of borosilicate glass (1.5 mm diameter) were pulled with a DMZ Zeitz Puller and had
an opening resistance between 3-5 MΩ filled with 0.5% biocytin intracellular solution
(chapter 3.5.1). In the glass pipettes a teflon-coated silver wire with a chloride tip was
inserted. To maintain a closed circuit a reference electrode with a silver-silver chlo-
ride pellet was placed in the bath solution and connected with the head stage of the
amplifier. For moving the patch pipette a hydraulically controlled micromanipulator
(MHW-3, Narishige) was used.
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To visualise the section an upright microscope (Axioskop, Zeiss) was used with a mag-
nification of 60x immersion objective and camera (PCO, CCD Imaging). To identify
astrocytes the wave length of 605 nm was applied by a fluorescence lamp (HBO100,
Zeiss). For recording the current of cells a patch-clamp amplifier (EPC-9, HEKA) was
used. With a software programme (TIDA, HEKA) the currents could be measured.
4.1.3 Whole-cell patch-clamp recording of astrocytes
The patch-clamp technique was developed around 1980 by Erwin Neher and Bert Sak-
mann (Neher and Sakmann, 1976). This technique allows to record currents of multiple
channels simultaneously, over the entire cell membrane.
Thereby, a patch pipette filled with internal solution was placed in the bath chamber.
Additionally, overpressure was applied to keep the pipette tip opened during approach-
ing the cell. Only fluorescenct cells at the wavelength of λmax = 605 nm and showing
the typical whole-cell current pattern for an astrocyte were selected for patch-clamp
recordings (Fig. 4.1a). After reaching the target cell the overpressure was taken away
and the cell was simultaneously clamped at -80 mV. For a stable recording over 20 min,
a tight cell-attached mode is essential. Therefore, low underpressure was applied to
obtain a close contact between the pipette tip and cell membrane until a high resistance
at 1 GΩ (Gigaseal) was achieved. After sealing a short underpressure suck was done to
open the cell membrane and to gain access.
Before accessing the cell, a fast artefact compensation (CFAST ) using a 30 kHZ and 10
kHz filter was applied to decline the artefact current generated by immersion of the
patch pipette and batch solution. After opening the cell the artefact data was filtered
with 10 kHz and 3 kHz, a measure for the access quality. For analysing the input and
series resistance the Igor Pro tool written by PD Dr. Ronald Jabs was used. This
calculates the series resistance based on the mathematical equation Rs =∆U/I(t0) and
Rm =∆U/I(t1)−R2 for the membrane resistance (Fig. 4.1b).
All cells were electrophysically identified by their whole-cell current pattern meaning
that over 50 ms 10 mV steps were applied towards depolarisation (+20 mV) and fol-
lowed by hyperpolarisation (-160 mV) (Fig. 4.1a). Depending on the presence of various
channels in the membrane, every cell shows a typical current cell pattern. For astrocytes
mainly the Kir channels determine its appearance.
As the biocytin internal solution contains K-gluconate, the liquid junction potential of
-12 mV was compensated during the measurements by adjusting the holding potential.
From KA-injected animals only the slice with a clear injection mark was taken and addi-
tionally, two previous slices and two following of the injection mark. In total a maximum
of 5 slices were considered being suitable for patching astrocytic gap junction coupling
(GJC). After 20 min filling of a patched astrocyte with biocytin, the slices were fixed in
4 % PFA for 24 hrs and stored in 1x PBS, pH 7.4 at 4◦C until immunohistochemistry
was performed.
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(a) (b)
Figure 4.1 Electrophysiological whole-cell patch-clamp analysis. (a) Applying de- and hyper-
polarising voltage steps, between -160 mV to +20 mV for 50 ms, allows to identify the cell type, as
every cell has its cell-type specific pattern. (b) The upper image shows an example for a 10 mV current
steps (upper line) of 50 ms duration. The picture below depicts a circuit diagramme of the whole-cell
mode. The series resistance (Rs) originates at the pipette tip and the resistance of the membrane (Rm)
depends on the cell membrane properties, characterised inter alia by different types of ion channels and
their density. The capacity (Cm) depends on the membrane surface area.
4.1.4 Analysis of astrocytic gap junction coupling
For the quantification of astrocytic GJC all cells filled with biocytin were counted by
using the software Fiji, plugin Cell counter by Kurt De Vos. Only cells achieving the fol-
lowing patch-clamp criteria were included in the analysis: i) at the beginning of recording
the cell had a membrane potential (MP) below -60 mV, ii) after 10 min the MP is within
a difference of 10 mV compared to the initial MP value, iii) during the first 10 min the
Rs was below 10 mV and the Rm not higher than 20 mV.
Cells were counted manually and identified, beside their biocytin fluorescence, by as-
trocytic markers for GFAP and S100β for their morphology. All images were counted
twice, once by myself and secondly by another experimentally blinded colleague, either
Camille Philippot, Dilaware Khan or Lukas Henning.
Evaluating the astrocytic GJC (number of biocytin-positive cells) only the ipsi- and
contralateral hippocampi were compared with each other, which were obtained from the
same brain slice.
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4.2 Immunohistochemistry
4.2.1 Tissue preparation
Adult animals were deeply anaesthesised by intraperitoneal (i.p.) injection with 100-
120 µl consisting of 80 mg/kg ketamine hydrochloride (WDT) and 1.2 mg/kg xylazine
hydrochloride (Sigma-Aldrich). After testing the hind paw reflexes the transcardial
perfusion was applied with 30 ml 1x PBS (4◦C) followed by 30 ml 4% PFA (4◦C). The
brain was removed and an additional fixation with 4 % PFA overnight was performed.
The storage of the tissue was maintained in 1x PBS at 4◦C until the sectioning was
done.
4.2.2 Staining
For stainings slices of either patch-clamp performed experiments with 200 µm thickness
for bioyctin labelling or slices from 4 % PFA-perfused animals were used, which were cut
into 40 µm thickness at a vibratom. Each slice was transferred into a well of a 24-well
plate and able to freely move during the whole staining procedure. To avoid unspecific
binding of antibodies, all slices were incubated in blocking solution for 2 hrs at RT,
containing 1x PBS 0.5-2% TritonX-100 for cell membrane permeabilisation and 10 %
normal goat serum (NGS). First antibodies were diluted in 1x PBS, 0.1-1 % TritonX-
100 and 2-5 % NGS and the slices were incubated overnight shaking at 4◦C. On the
following day every slice was washed three times with 1x PBS for 10 min each, followed
by incubation with its secondary antibody solution for 2 hrs at room temperature. After
washing them again three times with 1x PBS for 10 min the nuclei staining with Hoechst
(1:200 diluted in dH2O) was performed for 10 min at RT. A final washing step was
performed and all slices mounted with Aquapolymount on objective slides and covered
with cover slips. Before confocal imaging was performed the slides were stored at 4◦C
overnight to allow the best fixation.
4.2.3 Confocal microscopy
All immunofluorescent stainings were imaged at a laser scanning microscope (SP8, Le-
ica) either in standard or photon counting detection mode (8 bit). Image resolution was
1024 x 1024 pixels taken at a speed of 400 Hz. For the detection of Hoechst a photo-
multiplier tube was used, whereas for all other stainings hybrid detectors were aquired.
For the immersion objectives 40x and 63x a motor correction was performed to improve
the resolution, depth of penetration and signal strength. Biocytin filled astrocytes were
imaged using a 20x objective with the zoom factor 1.2. All z-stacks were taken in 2 µm
thick planes.
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Figure 4.2 Analysis of morphological alterations after SE. The thickness of str. rad. was
measured above the highest point of the granule cell layer (red arrow). The number of neurons in the
str. pyr. was counted above the peak of the DG (white arrow). The GCD was always measured at half
of the distance of the hilus (orange arrows).
4.2.4 Data analysis
The immunohistochemical stainings were quantified either with software Fiji/ImageJ or
Imaris8.0. The analysis of astrocytic GJC was performed like described in chapter 4.1.4.
Sections from epileptic animals were analysed for severity of sclerosis by evaluating the
GCD of the DG, the thickness of the str. rad. (using Fiji) and the loss of neurons
in the str. pyr. (using Imaris8.0). In the the DG the thickness of the granule cells
were measured as indicated in Fig. 4.2. Therefore, half of the distance between the tip
to the ”highest” point of the hilus was used as the criteria determining the thickness.
An orthogonal line giving the thickness was drawn at the upper and lower granule cell
”band” (orange arrows). Both values were meaned.
The shrinkage of str. rad. was measured directly above the ”highest” bow of the hilus
to the str. pyr. as shown in Fig. 4.2, red arrow. For determining the number of neurons
in the str. pyr. the cell type specific marker NeuN (labels neurons) was analysed with
the software Imaris8.0. The number of neurons was counted in a box of 360x120x40 µm,
which was placed directly above the hilus (Fig. 4.2, white arrow) in the NeuN fluores-
cence channel. With the Imaris spot tool, parameters were evolved for the counting of
NeuN soma. These counting parameters were kept the them in all images.
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4.3 Unilateral kainate mouse model and seizure activity
recording
4.3.1 Intracortical kainate injection
Kainic acid or kainate (KA) is a natural acid found in marine seaweed and produced
industrially known as (2S,3S,4S)-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid
(IUPAC name). It is a selective agonist at kainate receptors and potent excitant neu-
rotoxin. One injection of KA i.p. or into the brain is able to induce epileptic seizures,
as it was shown in several KA-induced mouse models of epilepsy (Araki et al., 2002;
Li et al., 2008; Mouri et al., 2008; Riban et al., 2002; Bedner et al., 2015). In this
project we used an unilateral intracortical KA mouse model of temporal lobe epilepsy
(TLE) (Bedner et al., 2015). It was developed from an intrahippocampal KA model,
which is commonly used in research (Riban et al., 2002; Gro¨ticke et al., 2008; Bouilleret
et al., 1999). The difference between these two models is that the intracortical applica-
tion is using a blunt cannula, which is slightly ”pushing” onto the hippocampus without
damaging it (like it is the case in the intrahippocampal model) (Fig. 4.3a). Further-
more, a progredient development of generalised spontaneous seizure activity is observed
in these animals, as well as morphological alterations like hippocampal sclerosis, which
is typical in MTLE. Sclerosis is characterised by the loss of pyramidal neurons in the
CA1 and the CA3, shrinkage of the str. rad. and GCD in the DG.
Moreover, the intracortical model, published in Bedner et al. (2015), has several advan-
tages compared with other commonly used epilepsy models of systemic KA or pilocarpin
injection: i) it shows very low mortality rate less than 5%, ii) the onset of seizure ac-
tivity is limited to the hippocampus, iii) its unilateral application allows the use of the
non-injected contralateral side as a control from the injected animal. The unilateral
KA injection was only performed with deeply anaesthesised animals, which were fixed
stereotactically in a microinjection unit (TSE Systems GmbH). Using a 0.5 µl microsy-
ringe (Hamilton) 70 nl consisting of 20 mM KA dissolved in 0.9% sterile NaCl was
injected into the animals’ right cortex slightly above the dorsal hippocampus with the
coordinates 1.9 mm posterior from bregma, 1.5 mm from the sutura sagittalis (midline)
and 1.7 mm from the skull surface. The cannula was kept for 2 min into its position to
limit the flow back along the cannula track. After removing the animals from the mi-
croinjection unit they either got a transmitter implantated or the skin was immediately
clamped, desinfected and the anaesthesia was stopped with Atipamezol (300 mg/kg) i.p.
injection.
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(a) (b)
(c)
Figure 4.3 KA-induced mouse model of TLE. (a) The intracortical KA injection is applied into a
single hemisphere, this side is termed ipsilateral. The non-injected side serves as control and is named
contralateral. (b) Seizure activity can be tracked by SeeTec observation system and allows the animals
to move freely in their cages. (c) Progression of seizure activity displays three phases, status epilepticus
(SE) is followed by the latent and chronic phase. Source: modified from Bedner et al. (2015)
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4.3.2 Transmitter implantation for EEG recording and video
monitoring
Electrographic seizures in mice were recorded with a wireless/ telemetric system from
DSI allowing the animals to move freely around in their cages. Therefore, all trans-
mitters TA10EA-F20 were cleaned in glutaraldehyd overnight before implanting them
into the animals. Adult animals were deeply anaesthesised with 40 mg/kg ketamine hy-
drochloride (WDT) and 0.3 mg/kg medetomidine (Cepetor, cp-pharma) i.p. injection.
After testing the hind paw reflexes, the fur was removed at the abdominal region and a
small skin incision was made. A tiny subcutanously passage allowed to move the trans-
mitter wires from the abdominal incision to the skull. The wires were placed into two
holes slightly posterior of the KA injection coordinates into the cortex and covered with
dental cement (Paladur). Finally, the skin was sutured and the anaesthesia stopped
(see above). Additionally, the animals were injected with 4 mg/kg carprofen i.p. to
reduce their pain. Due to the operation all animals got aftertreatment by monitoring
their body temperature rectally on a heating plate (TKM-0904, FMI). When their body
temperature was at 36.5◦C and the animals started to move, they were gently placed
back in their cages. To reduce the risk of infection 0.25% enfrofloxacin was given via
drinking water for at least one week after the surgery.
The signal from each transmitter was captured by a radio receiving plate (RPC-1, DSI)
on which the individual animals were placed. With the software Dataquest A.R.T 4.00
Gold/Platinum from DSI the signal was processed from digital output of the exchange
matrix into an analog output (Fig. 4.3b).
With two infrared cameras 8 animals could be video monitored simultaneously for addi-
tional approval of seizure severity. The data was displayed and stored with the network-
based programme from SeeTec Office 5 on a computer.
4.3.3 Data analysis
All telemetric EEG data was analysed manually following certain criteria. Potential
seizures could be confirmed by typical behaviour through video monitoring (see below).
For analysing the SE, only ictal events lasting more than 20 s followed by postictal de-
pression were added showing up within the first 12 hrs after KA injection. To determine
the duration of SE, it was defined as the time from the onset until no seizure activity
was recorded for at least 1 h. The duration of the latent period in which hardly any
seizures are present and the onset of chronic phase were correlated beside EEG with
convulsive behaviour of stage III-V defined by Racine’s classification (Racine, 1972).
For analysing electrographic seizures in the chronic phase, high-frequency spiking activ-
ity (up to 60 Hz) with gradually increasing amplitudes lasting about 60 s were taken
into account. Typically the seizure activity ended by an abrupt roll out of EEG called
postictal depression. Most chronic seizures were present with tonic-clonic or exclusive
clonic convulsions.
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4.4 Immunoprecipitation
4.4.1 Tissue preparation
ELISA of cytokines TNF-α and IL-1β was performed using FVB hGFAP-eGFP mice.
Adult animals were deeply anaesthesised with 100-120 µl consisting of 80 mg/kg ke-
tamine hydrochloride (WDT) and 1.2 mg/kg xylazine hydrochloride (Sigma) (i.p.). Af-
ter testing the hind paw reflexes, the thorax was opened and the blood sample was taken
from the heart with a multivette600 (Sarstedt). The blood was allowed to coagulate for
13-15 min and centrifuged at RT with 10.000 G for 5 min before the supernatant was
transferred into a 1.5 ml tube and centrifuged for 10 minutes at 1.000 G. Finally, the
serum was immediately frozen in liquid nitrogen and stored at -80◦C until it was used for
immunoprecipitation. Afterwards the transcardial perfusion was applied with 20 ml 1x
PBS at 4◦C. Both dorsal hippocampi were removed quickly and frozen in liquid nitrogen
and stored at -80◦C until the tissue was used for immunoprecipitation.
To clarify the cytokine profile during KA-induced SE, animals from different time points
were investigated: 1 hpi, 4 hpi and 1 day post injection. As negative controls, we injected
NaCl into the ipsilateral side of animals having the same age and breeding background.
They were decapitated at the same time points after injection. Additionally, samples
from LPS [10 mg/kg] i.p. injected animals were prepared 3 days after the injection.
These animals served as a positive control as the dose of 10 mg/kg is sufficient to cause
sepsis.
4.4.2 Tissue lysis
Frozen hippocampi were homogenised with a solution containing protease inhibitors
(chapter 3.5.3). Per 1 µg of tissue the 6.5x amount of solution was used and 10-20 beads
added. Using the device Precellys24 (Bertin technologies) the tissue was smoothly ho-
mogenised 2x 20 s at 5.000 rpm. After a short centriguation 2x RIPA buffer was pipetted
into each sample (same volume as used as for homogeneity solution) and incubated on
ice for at least 30 min. The lysate was centrifuged for 15 min with 20.000 rcf at 4◦C.
Total protein concentration was assayed with bicinchoninic acid (BCA) using 3 µl of
each sample. Probes were always pipetted in duplicates. Results with a variation of 5%
were discarded.
4.4.3 ELISA
Cytokine level detection was performed using a multispot enzym-linked immunosorbent
assay (ELISA) system kit K15048D from Mesoscale within one month after freezin them
in liquid nitrogen. To measure cytokine levels 50 µg of total protein from hippocam-
pus sample per well was used. For serum samples 2-fold dilution was used. With this
method, cytokine levels are specifically measured within small volume sample according
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to the sandwich immunoassay, meaning that detection antibodies conjugated with elec-
trochemiluminescent labels (MSD Sulfo-Tag) bind to the cytokine, which is also bound
by the capture antibody. That one finally emits light when voltage is applied to the
plate electrodes and allows a quantitative measure of the each cytokine in the sample,
which is proportional to its amount.
Lysates were mixed with diluent 41 as recommended in the kit’s manual and incubated
for 2 hrs at 600 rpm at RT. After 3x washing step with 1x PBS containing 0.05% Tween-
20, the sulfo-tagged antibody was mixed with diluent 45 (see manual) and incubated
at 600 rpm at RT for another 2 hrs followed by 3x washing. Finally Read Buffer T
was loaded and cytokine levels measured by using the device QuickPlex SQ120 (MSD).
ELISA was supervised by Dr. Frederic Brosseron and financially supported in the co-
operation with Prof. Dr. Michael T. Heneka.
4.4.4 Data analysis
For the analysis, results which are higher than the median lower limit of detection
(LLOD), like indicated in the Mesoscale manual, were used. Data points lower LLOD
are named as not detectable (n.d.) and excluded from the statistical analysis.
4.5 Statistics
All statistical analysis was performed with Origin (OriginLab, version 9, US), JMP (SAS
Institutes, version 10-11, US) and online available tools from astatsa.com.
Data is displayed as mean± SD and were statistically tested for their normal distribution
with Shapiro-Wilk. For comparing two groups either a parametric test (Students’ t-
test) or non-parametric test (Mann-Whitney-U test) was used. If a non-parametric
test was applied it will be indicated in the text and figures. More than two groups
were statistically tested by analysis of variance (ANOVA) with post-hoc Tukey HSD.
Differences between means were considered as being significant at p≤ .05 (*t-test or #
ANOVA).
Statistical analysis for significant changes in the seizure activity was obtained within
one condition by comparing the seizures from a time point of interest with the previous
time point of seizure data set. If two or more conditions were compared with each other,
like in chapter 5.6.1, the seizure activity was compared between the conditions for the
same time point.
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5.1 Acute and chronic SE-induced changes in TLE
The unilateral intracortical kainate (KA) mouse model (Fig. 5.1a) fits best for under-
standing the development of human MTLE-HS. Beside the very low mortality in this
model the changes observed on the ipsilateral hippocampus are exclusively due to the
KA-induced hyperactivity and not resulting from damaged tissue by the injection sy-
ringe. Furthermore, published data have shown that the model mimicks very closely the
chronic human disorder (Bedner et al., 2015). Therefore, we assume it serves also as
an experimental model of TLE to study the mechanisms underlying the pathogenesis.
Animals, which were injected exclusively with KA and did not receive further adminis-
tration of other substances, are named as ”KA-only” animals in this work.
The following time points were investigated in this study: 4 hrs, 1 day, 3-5 days, 14
days, 28 days, 2 months and 3 months post KA injection.
5.1.1 EEG recording
All hGFAP-eGFP animals injected with KA-only developed status epilepticus (SE),
which was characterised by repetitive seizure activity without regaining consciousness
inbetween (Lowenstein et al., 1999) (Fig. 5.1b). The SE started immediately after KA
injection and lasted on average 4.4 ± 2.4 hrs (n = 69) (Bedner et al., 2015).
After SE, a latent phase of 3 ± 2.4 days (n = 4) with no seizure activity was observed.
After that period animals developed secondaryly generalised spontaneous seizures lasting
20 - 80 s (Bedner et al., 2015). The seizure activity during the first 4 weeks after SE
is shown in Fig. 5.1c. Comparing the seizure frequency between the first, second and
third months revealed no significant increase (first vs. second month p=0.535, first vs.
third month p=0.481, second vs. third month p=0.899).
Video-monitoring analysis revealed that spontaneous electrographic seizures were always
accompanied by behavioural tonic-clonic convulsions.
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(a) (b)
(c)
Figure 5.1 Seizure activity in hGFAP-eGFP mice after unilateral intracortical KA injec-
tion. (a) A single KA injection was applied unilaterally into the cortex. (b) All KA-only animals (n
= 4) developed SE, which is in agreement with previously published data by Bedner et al. (2015). (c)
After SE the seizure frequency rapidly increased within 3 months.
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5.1.2 Morphological changes
Several morphological changes like GCD in the DG, the loss of pyramidal neurons in the
CA1 region and shrinkage of the str. rad. are well known from epileptic tissue resected
from patients with pharmacoresistant TLE-HS (Blu¨mcke et al., 1999; Thom, 2014).
These hallmarks of sclerosis can be found also in the unilateral intracortical KA mouse
model and therefore, this model serves very well for investigating the morphological
changes occurring during the development of MTLE (Bedner et al., 2015).
For each parameter 3 slices per animal and 3 animals in total were stained with cell type
specific markers. For the analysis of cell dispersion the neuronal marker NeuN was used
(like described in chapter 4.2.4) in KA-only animals. Three months after SE induction
the granule cell layer was significantly dispersed on the ipsilateral side (p=0.001*) (see
table 5.7, Fig. 5.16 B2, yellow arrow). Additionally, the number of pyramidal neurons
was quantified by NeuN staining at the same time point (see chapter 4.2.4). On the
ipsilateral side a significant reduction by 87% was detected (p=0.001*) (see table 5.8,
Fig. 5.16 B2, white arrow). Three months post SE induction also the width of the str.
rad. was significantly shrunken on the ipsilateral hippocampus (p=0.001*) (see table
5.9, Fig. 5.16 B2, red box).
5.1.3 Changes of the astrocytic coupling in TLE
Astrocytes in the hippocampus are connected with each other via gap junction channels
composed of Cx43 and Cx30 (D’Ambrosio et al., 1998). They form a very homogenous
network in the str. rad. of the CA1 region (Mishima and Hirase, 2010). The tracer
spread assay is a reliable approach to compare the astrocytic coupling strength. Biocytin
was chosen as a tracer, because it is well known to be small enough to efficiently diffuse
via GJ into the network (Rouach et al., 2008). It is easily applied via the intracellular
pipette solution into the patched cell.
In Fig. 5.2a,b two example images of biocytin tracer spread in hGFAP-eGFP mice are
shown, patched 4 hrs after KA injection. All patched cells were electrophysiologically
characterised (described in chapter 4.1.3) and displayed astrocyte typical large passive
current patterns. SR101 was used to visualise astrocytes (Schnell et al., 2012). Only
astrocytes on the contralateral side, but not on the ipsilateral, showed fluorescence. To
understand how impairment of astrocytic coupling contributes to the development of
TLE, different time points after KA injection were analysed. As already published in
Bedner et al. (2015) astrocytic coupling was significantly reduced ipsilaterally 4 hrs after
KA injection and completely vanished 3 months post injection. Further time points were
investigated to study the coupling strength within the progression of TLE (see table 5.1
and Fig. 5.2c).
After 28 days the astrocytic coupling was significantly reduced by 67% on the ipsilateral
hippocampus (p=0.004*). Animals, which were patched at the time points 4 hrs, 3 days,
5 days and 9 days post KA injection had received additional NaCl i.p. injection, as those
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were used as control condition for XPro1595 administration. Assuming that the NaCl
injection had no influence on the astrcytic GJC, all data gained from KA-only injected
animals with and without additional NaCl injection are displayed in the Fig. 5.2c.
Table 5.1 Astrocytic gap junction coupling in KA-only animals
time point no. of biocytin+ cells on statistical no. of slices
after KA injection contralateral side ipsilateral side t-test (no. of animals)
4 hpi 126 ± 16 63 ± 7 p=0.001* 11 (4)
3 dpi 174 ± 11 91 ± 21 p=0.003* 12 (3)
5 dpi 217 ± 79 158 ± 56 p=0.108 8 (2)
9 dpi 210 ± 39 172 ± 9 p=0.173 12 (3)
14 dpi 125 ± 41 98 ± 56 p=0.510 27 (8)
28 dpi 115 ± 41 38 ± 15 p=0.004* 20 (8)
In conclusion, the unilateral intracortical KA injection leads to seizure activity and mor-
phological changes closely mimicking human TLE. The astrocytic GJC was significantly
reduced within the first 3 days post SE promoting seizure activity. The astrocytic cou-
pling strength recovery during the onset of chronic seizure might have a positive impact
on reducing seizures. In the late chronic phase the seizures’ frequency increase was
accompanied by a complete loss of astrocytic coupling (Bedner et al., 2015).
53
Results
(a) (b)
(c)
Figure 5.2 Astrocytic coupling after SE-induced seizures. (a,b) A hippocampal astrocyte
was filled with biocytin, which diffuses through GJC into neighbouring astrocytes. The representative
examples show significantly reduced GJC 4 hrs post SE induction only on the ipsilateral hippocampus.
(c) Mean values of astrocytic GJC over time in dorsal hippocampal slices after SE induction. Number
in bars indicate the number of slices and in brackets the number of investigated animals is displayed.
A significant reduction in coupling was found within 3 days after SE. This effect is missing in the
late latent and early chronic phase 14 days post KA injection. Progression of epileptogenesis leads to
the loss of astrocytic coupling in the late chronic phase. Asterisk indicates significant difference from
contralateral hippocampus.
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5.2 Acute SE-induced changes in IL-1β and TNF-α
Cytokine changes are often reported to occur in epilepsy. Not only Ravizza et al. (2008)
and Ashhab et al. (2013) found significant changes in TNF-α and IL-1β in human epilep-
tic tissue, but also in several animal models of epilepsy cytokines play an important role
(Ravizza et al., 2008; Ashhab et al., 2013; Vezzani et al., 1999; Vezzani et al., 2002;
Penkowa et al., 2005).
It was shown in Bedner et al. (2015) that cytokines signficantly reduce the astrocytic
coupling strength, while incubating WT slices in IL-1β and TNF-α for several hours.
To proof that the reduction of astrocytic coupling is caused by TNF-α, its antago-
nist XPro1595 (Xencor) was additionally applied in the incubation solution. Indeed,
Alexander Dupper could demonstrate that the inhibition of TNF-α by co-incubation
with XPro1595 prevented uncoupling in situ (Dupper, 2014).
Therefore, IL-1β and TNF-α play an important role in the loss of astrocytic coupling
and the application of their antagonists is preventive in acute brain slices. Hence, it is
worth to study these cytokines and their role in pathophysiological conditions, like TLE
in vivo.
5.2.1 ELISA analysis of cytokine levels in the dorsal hippocampus
IL-1β and TNF-α play a pivotal role in inflammatory processes and act differently
depending on their concentration, activation of molecular signalling cascades and the
related disease.
In previous papers varying results of cytokine levels were published (Vezzani et al., 2002;
Penkowa et al., 2005; Patel et al., 2017). This discrepancy emerges from the use of diverse
animal models. The measurement of IL-1β and TNF-α in our intracortical KA-induced
mouse model by ELISA was necessary to assess the molecular mechanisms behind the
effect of XPro1595. We have chosen the time points 1 hr, 4 hrs and 1 day post KA
injection. As controls we used sham-injected animals to evaluate the influence of the
injection procedure itself. For each condition and time point 4 animals were used. The
samples were prepared like described in chapter 4.4.2. To study local cytokine changes
samples from dorsal hippocampi were taken.
In sham-injected animals, at all time points IL-1β levels were too low to be detected on
the contralateral side and therefore stated as not detectable (n.d.)(see table 5.2). On the
ipsilateral hippocampus after 1 hr the cytokine was not detectable. KA-only animals
displayed significantly increased IL-1β on the ipsilateral hippocampus 4 hrs after SE
induction. No IL-1β was detected ipsilaterally at the very early time point 1 hr post
KA injection.
No difference was found between the sham and KA-only mice after 4 hrs (p=0.762),
implying that the upregulation of IL-1β in both conditions was mainly due to the needle
placement in the cortex itself. Surprisingly, elevated IL-1β levels were detected on
the contralateral hippocampus in KA-only injected animals, but not in sham mice,
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Table 5.2 Changes in IL-1β concentration after different time points of injection
time point condition IL-1β concentration in pg/ml statistical no.
after SE induction contralateral side ipsilateral side t-test of animals
1 hpi sham not detectable not detectable 4
KA not detectable not detectable 4
4 hpi sham not detectable 2.7 ± 0.85 4
KA 1.76 ± 0.55 3.26 ± 0.85 p=0.029* 4
1 dpi sham not detectable 0.18 ± 0.06 4
KA 0.53 ± 0.39 0.64 ± 0.25 p=0.899 4
suggesting that KA-induced seizures lead to an upregulation of IL-1β levels in the non-
injected side (Fig. 5.3).
Figure 5.3 IL-1β levels in KA-injected animals. IL-1β levels were elevated in KA-only and sham
animals on ipsilateral hippocampus 4 hrs after injection, indicating that the injection per se caused
a IL-1β release. That was significantly decreased 24 hrs post injection. Asterisk indicates significant
difference from contralateral hippocampus. Diamonds point out significant difference from another
treated group.
In KA-injected animals TNF-α significantly increased 4 and 24 hrs post-injection (table
5.3). Remarkably, TNF-α could not be detected on the ipsilateral side 1 hr post SE
induction, and on the contralateral hippocampus TNF-α was measured slightly above
detection level. As shown in Fig. 5.4 in sham-injected animals no significant difference
of TNF-α levels were detected in both hippocampi.
Regarding the observation that the injection causes an upregulation of the cytokine
per se, the difference of TNF-α levels is significantly 21-fold higher in KA-only mice
(p=0.008*).
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Table 5.3 Changes in TNF-α concentration after different time points of injection
time point condition TNF-α concentration in pg/ml statistical no.
after SE induction contralateral side ipsilateral side t-test of animals
1 hpi sham not detectable 1.0 ± 0.46 4
KA not detectable 0.34 ± 0.18 4
4 hpi sham 0.23 ± 0.06 3.19 ± 1.44 p=0.899 4
KA 1.63 ± 0.38 23.85 ± 10.62 p=0.001* 4
1 dpi sham not detectable 0.37 ± 0.07 4
KA 2.14 ± 1.24 5.1 ± 0.96 p=0.009* 4
Figure 5.4 TNF-α levels in KA-injected animals. Four hours after sham injection increased levels
were detected on the ipsilateral hippocampus, indicating an activation by the injection per se, which
is significantly diminished after 24 hrs. In KA-only injected animals, TNF-α levels were significantly
elevated on the ipsilateral side 4 and 24 hrs post injection. Asterisks indicate significant difference from
contralateral hippocampus. Diamonds point out significant difference from another treated group.
In summary, the comparison of cytokine levels indicate that TNF-α was significantly
higher on both sides in KA-injected animals than IL-1β levels. Elevated cytokine levels
resulted from KA-induced SE and not from the injection needle.
5.2.2 ELISA analysis of cytokine levels in the serum
Serum was collected from the same animals, which were used for the ELISA analysis in
the dorsal hippocampus. We investigated their changes in the serum. Therefore, the
samples were prepared like described in chapter 4.4.1 and assessed by ELISA (chapter
4.4.3). TNF-α levels were higher than IL-1β in the blood but no significant differences
between the different time points or treatments were observed (Fig. 5.5). As a positive
control we used animals injected i.p. with 10 mg/kg LPS, which is a commonly used
model for sepsis (Fink, 2014; Buras et al., 2005).
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Figure 5.5 Serum levels of TNF-α and IL-1β in KA-injected animals. TNF-α serum levels
were elevated compared with IL-1β levels at all time points and in all conditions. LPS i.p. injection
served as a positive control.
5.2.3 Incubation with antagonists for proinflammatory cytokines
To clarify which influence TNF-α and IL-1β have in the development of TLE in our KA
model we incubated acute brain slices in situ from 1 day post KA-injected animals with
the solTNF-α antagonist XPro1595 [10 µg/ml] and IL-1β receptor antagonist Anakinra
[10 ng/ml]. As the time of incubation with antagonists might have an impact on the
astrocytic GJC, two groups were set up: GJC in slices being incubated below 3 hrs or
above. We found no significant effect between the two groups with different incubation
times (contralateral p=0.454, ipsilateral p=0.178). Moreover, no significant difference
between the contralateral and ipsilateral hippocampus was seen (149 ± 23.3 vs. 122 ±
43.3 biocytin positive cells, p=0.299, n=17 slices from 4 animals) (Fig. 5.6).
In conclusion, these experiments demonstrate that the inhibition of solTNF-α and IL-1β
restored the astrocytic gap junction coupling in TLE animals 1 day post KA injection.
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Figure 5.6 Astrocytic coupling is restored by in situ incubation with TNF-α and IL-1β
antagonists. One day after KA injection, acute brain slices were incubated with cytokine antagonists
Anakinra and XPro1595. No difference in the extent of tracer diffusion could be detected between the
contra (c)- and ipsilateral (i) hippocampus.
5.3 Comparison of KA-only versus XPro Prev
XPro1595 was administered three times i.p. in 3-days interval before KA injection, as
indicated in Fig. 5.7a. This condition is termed as ”XPro Prev” animals in this work.
We measured the seizure activity, investigated morphological changes and the astrocytic
coupling up to 3 months post KA injection.
5.3.1 EEG recording
All animals were injected with XPro1595 before KA administration and developed SE,
which qualitatively did not differ from animals without XPro1595 treatment (Fig. 5.7a,
b). Intriguingly, the animals did not develop secondary generalised spontaneous seizures.
The spontaneous seizure activity is depicted in table 5.6. In accordance with the EEG
data, no behavioural tonic-clonic seizures could be detected by video-monitoring in XPro
Prev treated KA-injected animals. Recordings were terminated 3 months post SE in-
duction and animals were either used for patch-clamp analysis or were perfused for
morphological analysis.
Accordingly, the treatment with XPro1595 had an impact on the development of epilepsy.
The seizure activity of XPro Prev was recorded over 3 months after the KA injection and
was compared with KA-only animals. After the first week no significant changes between
the conditions were observed (p=0.376). From the second week on, the seizure frequency
was significantly reduced in XPro Prev treated animals compared with KA-only animals
(2nd week p=0.001#, 3rd week p=0.019#). Notably, after 1, 2 and 3 months, XPro
Prev treated animals continued to show no generalised spontaneous seizure (Fig. 5.7c).
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(a) (b)
(c)
Figure 5.7 Seizure activity in XPro Prev animals. (a) To investigate effects of solTNF-α in
experimental epilepsy XPro1595 was given three times i.p. in 3-days interval before KA injection to
ensure sufficient levels of the inhibitor. (b) All XPro Prev animals (n = 6) developed SE, which is
in agreement with the observations from KA-only animals. Qualitatively XPro injection had no effect
on the seizure activity during SE. (c) After SE the seizure activity was completely inhibited in XPro
Prev animals indicating that inactivation of solTNF-α can prevent the development of seizure activity.
Asterisks indicate significant difference from another treated group.
60
Results
5.3.2 Morphological changes
Three months post KA-only injection animals without further treatment showed a sig-
nificant loss of pyramidal neurons, shrinkage of the str. rad. and a pronounced GCD
in the DG. To clarify if pre-application of the solTNF-α blocker XPro1595 is able to
alter these typical morphological changes in epilepsy, 3 slices per animal and in total 3
animals were stained with cell type specific markers.
For the analysis of cell dispersion the neuronal marker NeuN was used in the DG (like
described in chapter 4.2.4) in XPro Prev animals. Three months post SE the granule
cell layer was found not to be dispersed on the ipsilateral side (p=0.899) (see table 5.7,
Fig. 5.16 C2, yellow arrow). In KA-only animals the neurons on the ipsilateral side
were significantly dispersed compared with the width of granule cell layer in XPro Prev
(p=0.001#). That indicated that inhibiting solTNF-α had an impact on the develop-
ment of GCD.
Additionally, the number of pyramidal neurons was quantified by NeuN staining at the
same time point (see chapter 4.2.4). On the ipsilateral hippocampus a significant reduc-
tion of 44% was detected (p=0.002*) (see table 5.8, Fig. 5.16 C2, white arrow). Most
importantly, in XPro Prev animals the extent of neuronal loss was significantly less
compared with KA-only ipsilateral side (p=0.004#), showing that inhibiting solTNF-α
before SE induction is able to signficantly prevent neuronal death (Fig. 5.14).
Three months post SE the width of str. rad. was not shrunken (p=0.899) (Fig. 5.16
C2, red box). In KA-only injected animals the ipsilateral side was significantly shrunken
compared with the corresponding contralateral, moreover the ipsilateral hippocampus
was significantly thinner than in sham injected animals (p=0.001#) (table 5.9). Pre-
treatment with XPro1595 even prevented a significant shrinkage of str. rad. comparing it
with KA-only ipsilateral hippocampus (p=0.001#). Neither alterations between contra-
and ipsilateral hippocampi (p=0.899) nor the ipsilateral sides of XPro Prev and sham-
injected mice displayed a significant difference (p=0.595) (Fig. 5.15).
In conclusion, the administration of XPro1595 before KA injection attenuated the pyra-
midal neuronal loss, prevented GCD and shrinkage of the str. rad.. That indicates
that solTNF-α supports neuronal survival and attenuates astrogliosis in the KA-induced
mouse model of TLE.
5.3.3 Loss of the astrocytic coupling is prevented by XPro1595
The animals were injected with XPro1595 before KA injection and decapitated at dif-
ferent time points to determine how the astrocytic coupling strength changes. The
astrocytic coupling strength was measured at several time points to study the progres-
sion of TLE (Fig. 5.8c). For the acute phase, 4 hrs after SE induction was chosen,
for the latent phase 3 and 5 days and for the chronic phase 3 months (table 5.4). No
significant difference was observed between the contralateral and ipsilateral number of
biocytin positive cells at any time point, indicating that XPro1595 application before
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inducing SE has an impact on the astrocytic GJC.
To proof that the observed coupling is an effect of XPro1595, we injected NaCl i.p. be-
fore KA administration, instead of XPro1595. Assuming that the additional injection of
NaCl into the abdomen has no impact on the astrocytic GJC in the hippocampus, the
results from those animals are shown in the same figure together with KA-only injected
animals (without additional NaCl administration) (Fig. 5.2c). Therefore, a comparison
of astrocytic coupling strength between KA-only injected and XPro Prev administered
animals was done at the following time points: 4 hpi, 3 dpi and 3 mpi.
At the early phase, the SE-induced uncoupling in KA-only animals displayed 50% reduc-
tion in astrocytic GJC, whereas XPro Prev animals showed no significant impairement
in coupling (p=0.478) (see table 5.4). This also applies to the 3 dpi time point; in
KA-only injected animals the ipsilateral astrocytic coupling was significantly reduced by
48% (p=0.003*). In XPro Prev treated animals no significant alteration was detected
(p=0.309), demonstrating that XPro Prev treatment indeed prevented SE-induced un-
coupling. During the chronic phase at 3 mpi, XPro1595 application also prevented
the reduction of astrocytic GJC (p=0.681), whereas in KA-only animals complete loss
of astrocytic coupling was detected on the ipsilateral hippocampus (see Bedner et al.,
2015).
Table 5.4 Astrocytic gap junction coupling in XPro Prev treatment
time point no. of biocytin+ cells on statistical no. of slices
after KA injection contralateral side ipsilateral side t-test (no. of animals)
4 hpi 116 ± 17 103 ± 36 p=0.478 15 (5)
3 dpi 171 ± 24 195 ± 26 p=0.309 11 (3)
5 dpi 253 ± 73 207 ± 14 p=0.340 14 (3)
3 mpi 145 ± 17 154 ± 29 p=0.681 13 (3)
In conclusion, the application of XPro1595 before KA injection prevented SE-induced
astrocytic GJ uncoupling and attenuated the development of sclerosis. Furthermore, it
blocked almost completely the development of chronic seizures.
Those results indicate that the application of a solTNF-α inhibitor can prevent the
development of epilepsy.
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(a) (b)
(c)
Figure 5.8 Loss of astrocytic coupling is prevented in XPro Prev animals. (a,b) Hippocampal
astrocytes were filled with biocytin. The representative examples display no significantly reduced GJC
in XPro Prev treatment prior to KA injection. (c) Mean values of astrocytic GJC over time in dorsal
hippocampal slices after SE induction. Number in bars indicate the number of slices and in brackets
the number of investigated animals is displayed. No significant impairment of astrocytic coupling was
found at any time point.
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5.4 Comparison of KA-only versus XPro Resc
Knowing that XPro1595 prevents KA-induced SE prompted us to ask whether the ap-
plication of solTNF-α inhibitor can attenuate the progression of TLE. Therefore, we
injected XPro1595 three times with the same concentration in 3-days interval after the
KA injection, trying to rescue the TLE related characteristics. This condition is termed
as ”XPro Resc” animals in this work. We recorded the seizure activity, investigated
morphological changes and astrocytic GJC up to 3 months post KA injection.
5.4.1 EEG recording
All animals within the XPro Rescue group (n = 14) were injected first with KA and 4
hrs later with XPro1595. In 3-days interval, all animals received two further XPro1595
i.p. injections on day 3 and 6 after SE induction (Fig. 5.9a). All animals developed
SE, which started immediately after KA injection and qualitatively did not differ from
animals without XPro1595 treatment (Fig. 5.9b). The SE was followed by a latent
period of 4.4 ± 3.2 days. The recorded spontaneous seizure activity up to 3 months
after SE induction is displayed in Fig. 5.9c and in table 5.6.
For seizure activity monitoring within the first month post SE, we recorded 14 ani-
mals. For the later time points 2 months post SE we studied 5 animals and 4 animals
up to 3 months post injection. Video-monitoring analysis revealed that spontaneous
electrographic seizures were always accompanied by behavioural tonic-clonic seizures.
Recordings were terminated 3 months post SE induction and animals were either used
for patch-clamp analysis or were perfused for morphological analysis.
The development of seizure frequency within the first month after SE induction did not
significantly improved in XPro Prev animals, comparing the seizure activity weekly with
each other (first vs. second week p=0.200, first vs. third week p=0.220, second vs. third
week p=0.899). Interestingly, XPro Resc animals displayed a significant reduction in
the seizure frequency compared with KA-only animals in the 2nd and 3rd month post
SE (from 1st to 2nd month p=0.001#; from 2nd to 3rd month p=0.010#).
Thus, the treatment with XPro1595 after SE induction significantly reduced the seizure
frequency in the long-term.
5.4.2 Morphological changes
Three months post SE, KA-only animals showed significant loss of pyramidal neurons,
shrinkage of the str. rad. and pronounced GCD. To clarify if application of the solTNF-
α blocker XPro1595 is able to prevent or dampen these typical morphological changes,
3 slices per animal and in total 3 animals were stained with cell type specific markers.
For the analysis of cell dispersion the neuronal marker NeuN was used in the DG (like
described in chapter 4.2.4) in XPro Resc animals. Three months post SE the granule
cell layer was found not to be dispersed on the ipsilateral side (p=0.167) (see table
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(a) (b)
(c)
Figure 5.9 Seizure activity in KA-injected animals with or without post-treatment of
XPro1595. (a) To assess the impact of solTNF-α, XPro1595 was given three times after KA at 3-
days interval. The first i.p. injection was administered 4 hrs after KA injection, followed by two more
XPro1595 injections 3 and 6 days after SE induction. (b) During the first 4 hrs all animals developed
SE, which was qualitatively similar to KA-only animals. XPro1595 injection itself is not inhibiting the
SE caused by KA injection. (c) After the latent period, secondary generalised spontaneous seizures are
present in XPro Resc animals, which are however, significantly reduced within the 2nd month. Asterisks
indicate significant difference from another treated group.
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5.7, Fig. 5.16 D2, yellow arrow). In KA-only animals the neurons on ipsilateral side
were significantly dispersed compared with the width of granule cell layer in XPro Resc
(p=0.001#) (Fig. 5.13). That indicated that inhibiting solTNF-α had an impact on the
development of GCD.
Additionally, the number of pyramidal neurons was quantified by NeuN staining at the
same time point (see chapter 4.2.4). On the ipsilateral hippocampus a significant reduc-
tion of 58% was detected (p=0.001*) (see table 5.8, Fig. 5.16 D2, white arrow). XPro
Resc animals showed a significant loss of neurons on the ipsilateral side compared with
sham mice (p=0.005#). Notably, it was less prominent in XPro Resc treated animals
than in KA-only (p=0.005#) (Fig. 5.14). The result indicated that inhibiting solTNF-α
4 hrs post injection prevented neuronal cell loss.
Three months post SE induction the width of the str. rad. was significantly shrunken on
the ipsilateral hippocampus compared with its contralateral side (p=0.001*) (see table
5.9, Fig. 5.16 D2, red box). Furthermore, the ipsilateral side of XPro Resc found to be
significantly changed from sham (p=0.001#). Remarkably, the str. rad. of XPro Resc
mice was significantly less shrunken than in KA-only animals (p=0.001#) (Fig. 5.15),
showing that XPro1595 post-injection is able to attenuate the shrinkage.
In conclusion, the administration of XPro1595 4 hrs, 3 and 6 days after KA injec-
tion attenuated the neuronal loss in CA1 and GCD and shrinkage of the str. rad. in
KA-induced mouse model of TLE. These results show that by subsequent XPro1595
application the development of epilepsy could be stopped.
5.4.3 Loss of astrocytic coupling is rescued by XPro1595
The animals were injected with XPro1595 after the KA injection and decapitated at
different time points to determine how astrocytic coupling strength changes (Fig. 5.10).
The time points 3, 5 and 9 days after SE induction were chosen. For the chronic phase
of epilepsy two time points at 28 days and 3 months after KA injection were investigated
(table 5.5). No significant difference was observed between the contralateral and ipsilat-
eral number of biocytin positive cells at any of the investigated time points, indicating
that XPro1595 application after SE has an restoring influence on the astrocytic GJC.
In conclusion, the application of XPro1595 post SE induction rescues SE-induced as-
trocytic GJ uncoupling and attenuates the development of sclerosis. Furthermore, it
decreased the frequency of chronic spontaneous seizures. These results indicate that the
inhibition of solTNF-α attenuates the development of TLE.
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Table 5.5 Astrocytic gap junction coupling in XPro Resc treatment
time point no. of biocytin+ cells on statistical no. of slices
after KA injection contralateral side ipsilateral side t-test (no. of animals)
3 dpi 164 ± 21 171 ± 12 p=0.651 11 (3)
5 dpi 213 ± 41 213 ± 23 p=1.000 14 (3)
9 dpi 167 ± 26 134 ± 31 p=0.093 10 (4)
28 dpi 243 ± 19 219 ± 5 p=0.094 8 (3)
3 mpi 171 ± 41 224 ± 31 p=0.083 14 (4)
Figure 5.10 Astrocytic coupling is restored in XPro Resc animals. The hippocampal astrocytic
GJC was visualised with the tracer spread assay and analysed. Mean values of astrocytic GJC over
time in dorsal hippocampal slices after SE induction are displayed. Number in bars indicate the number
of slices and in brackets the number of investigated animals is displayed. No significant reduction in
the astrocytic coupling was present at any time point. Asterisk indicates significant difference from
contralateral hippocampus.
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5.5 Comparison of KA-only versus XPro Chronic
XPro1595 is able to prevent and rescue the reduction of astrocytic coupling and conse-
quentially able to lower or even inhibit spontaneous seizure activity. Therefore, its po-
tential as therapeutical medication was studied. All animals received the first XPro1595
injection after their first generalised spontaneous seizure was identified in the EEG. That
happened mostly 4-6 days post SE induction. Two further XPro injections followed at
3-days interval to keep the application pattern (Fig. 5.11a). This condition is termed as
”XPro Chronic” animals in this work. We recorded the seizure activity and investigated
morphological changes up to 3 months post KA injection.
5.5.1 EEG recording
XPro Chronic treated animals were injected with XPro1595 i.p. after detecting their
first generalised spontaneous seizure after the latent period. All animals (n = 5) devel-
oped SE, which started immediately after KA injection and qualitatively did not differ
from animals without XPro1595 treatment (Fig. 5.11b). The SE was followed by a
latent phase of 3.2 ± 1.64 days. The recorded spontaneous seizure activity is displayed
in Fig. 5.11c and in table 5.6.
Video-monitoring analysis revealed that spontaneous electrographic seizures were ac-
companied by behavioural tonic-clonic seizures. Recordings were terminated 3 months
post SE induction and the animals were perfused for morphological analysis.
Comparing the seizure frequency within the first month after SE induction, neither a
significant improvement was observed nor a significant difference with KA-only mice
without XPro1595 (1st week p=0.661, 2nd week p=0.137, 3rd week p=0.343, 4th week
p=0.062). In the 2nd and 3rd month after SE induction, XPro Chronic mice displayed
a significant reduction in seizure frequency compared with KA-only mice (2nd month
p=0.001#; 3rd month p=0.021#).
Thus, the treatment with XPro1595 after the first generalised spontaneous seizure and
two further XPro1595 injections, significantly reduced the seizure frequency in the long-
term. Therefore, XPro1595 might be considered for therapeutical approach as it de-
creased seizure acitivity, which is a clinical parameter and read out for the efficiency of
a therapeutical drug.
5.5.2 Morphological changes
To elucidate, if application of the solTNF-α blocker XPro1595 after the first generalised
spontaneous seizure followed by two more XPro1595 injections, are still able to attenuate
the development of hippocampal sclerosis, 3 slices per animal and in total 3 animals were
stained with cell type specific markers.
For the analysis of cell dispersion the neuronal marker NeuN was used in the DG (like
described in chapter 4.2.4) in XPro Chronic animals. Three months post SE induction
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(a) (b)
(c)
Figure 5.11 Animals treated with XPro1595 after occurance of the first generalised spon-
taneous seizure. (a) To study the therapeutical potential of XPro1595, it was injected after animals
had developed their first generalised spontaneous seizure, followed by two further XPro1595 injections
in 3-days interval. (b) All XPro Chronic animals (n = 5) developed SE, which is in agreement with
the observation from control animals. (c) Animals treated with XPro1595 after occurance of the first
spontaneous seizure, the frequency was not altered within the first month, but was significantly reduced
in long-term. Asterisks indicate significant difference from another treated group.
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the granule cell layer was found not to be dispersed on the ipsilateral side (p=0.899)
(see table 5.7, Fig. 5.16 E2, yellow arrow). In KA-only animals the neurons on the
ipsilateral side were significantly dispersed compared with the width of granule cell layer
in XPro Chronic (p=0.001#) (Fig. 5.13). That indicated that inhibiting solTNF-α had
an impact on the development of GCD.
Additionally, the number of pyramidal neurons was quantified by NeuN staining at the
same time point (see chapter 4.2.4). On the ipsilateral hippocampus a significant reduc-
tion of 54% was detected (p=0.002*) (see table 5.8, Fig. 5.16 E2, white arrow). XPro
Chronic conditions showed a significant loss of neurons on the ipsilateral side compared
with sham mice (p=0.001#). Giving XPro1595 after the first spontaneous generalised
seizure the loss of neurons is not significantly different from KA-only mice on ipsilateral
side (p=0.051) (Fig. 5.14).
Three months after SE induction the width of the str. rad. was significantly shrunken
on the ipsilateral hippocampus compared with its contralateral side (p=0.001*) (see
table 5.9, Fig. 5.16 E2, red box). Furthermore, the ipsilateral side of XPro Chronic
animals found to be significantly different from sham (p=0.001#). Remarkably, the str.
rad. of XPro Chronic mice was significantly less shrunken than in KA-only animals
(p=0.001#) (Fig. 5.15), showing that XPro1595 post-injection is able to attenuate the
shrinkage even after the first spontaneous generalised seizure occured.
In conclusion, the application of XPro1595 after the first generalised spontaneous seizure
and two further XPro1595 injections, attenuated the development of sclerosis. Further-
more, it decreased the frequency of generalised spontaneous seizures. These results indi-
cate that the inhibition of solTNF-α attenuates the development of TLE at a clinically
relevant time point.
5.6 XPro1595 treatments - Comparison with each other
5.6.1 Spontaneous seizure activity
The treatment with XPro1595 had an impact on the development of TLE. The seizure
activity was recorded up to 3 months post KA injection and was compared with KA-only
animals. The data of KA-only and all XPro1595 treated animals is displayed in Fig.
5.12 and in table 5.6.
Within the first month neither significant changes between the conditions XPro Prev and
XPro Chronic were observed (1st week p=0.088; 2nd week p=0.103; 3rd week p=0.255;
4th week p=0.324) nor between XPro Resc and XPro Chronic (1st week p=0.899; 2nd
week p=0.493; 3rd week p=0.616; 4th week p=0.685). Only between XPro Prev and
XPro Resc a significant change in spontaneous seizure activity was observed within
the first 4 weeks (1st week p=0.041#; 2nd week p=0.002#; 3rd week p=0.016#; 4th
week p=0.033#). No differences between XPro treatments existed in the long-term (2nd
month Prev vs. Resc p=0.899, Prev vs. Chronic p=0.899, Resc vs. Chronic p=0.899; 3rd
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month Prev vs. Resc p=0.899, Prev vs. Chronic p=0.899, Resc vs. Chronic p=0.899),
showing that XPro1595 is able to efficiently decrease seizure activity in the chronic phase
of epilepsy, even administered post-treatment.
Figure 5.12 Seizure activity up to 3 months after epilepsy induction. Seizure activity was
completely inhibited in XPro Prev animals, indicating that inactivation of solTNF-α prevented the
development of seizure activity. Both XPro post-treatment conditions displayed a significant decrease
in seizure frequency 8 and 12 weeks post SE, indicating that the application of XPro1595 significantly
decreased seizure activity in the long-term. Diamonds point out significant difference from another
treated group.
Table 5.6 Mean values of seizure activity in KA-only and XPro1595 treated animals
week KA-only XPro Prev XPro Resc XPro Chronic
after SE mean ± SD n mean ± SD n mean ± SD n mean ± SD n
1 0.47 ± 0.31 4 0 ± 0 6 0.57 ± 0.53 14 0.61 ± 0.51 5
2 1.89 ± 0.80 4 0.05 ± 0.12 6 1.34 ± 0.82 14 1.16 ± 0.29 5
3 1.75 ± 1.11 4 0.05 ± 0.12 6 1.21 ± 0.91 14 1.04 ± 0.84 5
4 2.86 ± 0.76 3 0 ± 0 6 1.56 ± 1.45 14 1.32 ± 0.90 5
8 4.82 ± 2.15 6 0 ± 0 6 0.46 ± 0.51 5 0.37 ± 0.41 5
12 4.99 ± 3.26 6 0 ± 0 6 0.41 ± 0.53 4 0.25 ± 0.41 5
In conclusion, the treatment with XPro1595 reduced the seizure frequency in the long-
term and suppressed the progression of epileptogenesis.
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5.6.2 Morphological changes
Three months post SE induction HS was present in KA-only animals (chapter 5.1.2).
In XPro treated animals some of the sclerosis characteristics are less promiment or even
prevented. Fig. 5.16 shows an overview of sham, KA-only, XPro Prev, XPro Resc and
XPro Chronic treated animals 3 months after SE induction.
Fig. 5.13 depicts the effect of XPro1595 treatment on GCD 3 months after SE. Whereas
in KA-only animals the neurons on the ipsilateral side were significantly dispersed, the
width of granule cell layer in all XPro1595 conditions showed no changes (table 5.7).
Furthermore, no significant difference of GCD between the XPro1595 treatments were
found (Prev vs. Resc p=0.44; Prev vs. Chronic p=0.899; Resc vs. Chronic p=0.141).
That indicated that inhibiting solTNF-α prevented the development of GCD.
Figure 5.13 Effect of XPro1595 treatment on GCD 3 months after SE induction. GCD
was most prominent in KA-only animals. In XPro1595 treated animals the granule cell layer was not
significantly different between the contra- and ipsilateral hippocampus 3 months after SE, whereas
KA-only animals showed significantly increased width of GCD on the ipsilateral side. These results
demonstrate that XPro1595 inibits the development of GCD. Asterisk indicates significant difference
from contralateral side.
Table 5.7 Granule cell dispersion 3 months after SE induction
hippocampal sham KA-only XPro Prev XPro Resc XPro Chronic
side width in µm width in µm width in µm width in µm width in µm
contralateral 53 ± 2 63 ± 2 62 ± 4 63 ± 2 59 ± 1
ipsilateral 52 ± 4 202 ± 9 66 ± 2 76 ± 2 62 ± 1
t-test p=0.899 p=0.001* p=0.899 p=0.167 p=0.899
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Fig. 5.14 displays the number of pyramidal neurons in sham, KA-only and XPro1595
treated animals 3 months post Se induction. There was no significant difference between
XPro1595 treatments comparing ipsilateral neuronal loss between each other (Prev vs.
Resc p=0.607; Prev vs. Chronic p=0.178; Resc vs. Chronic p=0.899). However, neu-
ronal loss in XPro Prev is not significantly altered compared with sham, indicating that
XPro1595 application prior to KA-induced SE prevents the death of pyramidal neurons
in CA1.
Figure 5.14 Effect of XPro1595 treatment on the number of pyramidal neurons 3 months
after SE induction. KA-only treated animals showed almost complete loss of pyramidal neurons in
the ipsilateral hippocampus. Ipsilateral neuronal numbers were also reduced in all XPro1595 conditions,
but the extent of neurodegeneration is significantly less pronounced in XPro Prev and Resc animals
than in KA-only animals. Asterisks indicate significant difference from contralateral hippocampus.
Diamonds point out significant difference from another treated group.
Table 5.8 Pyramidal CA1 neurons 3 months after SE induction
hippocampal sham KA-only XPro Prev XPro Resc XPro Chronic
side no. of neurons no. of neurons no. of neurons no. of neurons no. of neurons
contralateral 85 ± 14 101 ± 27 111 ± 30 113 ± 10 89 ± 18
ipsilateral 84 ± 11 13 ± 3 62 ± 37 48 ± 18 41 ± 2
t-test p=0.899 p=0.001* p=0.002* p=0.001* p=0.002*
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In Fig. 5.15 and table 5.9 the effect of XPro1595 treatment on the width of the str. rad.
is shown in sham, KA-only and XPro1595 treated animals 3 months after SE induction.
The ipsilateral side between XPro Prev and both XPro1595 post-treatments displayed
a significant change (Prev vs. Resc/Chronic p=0.001#). However, no significant differ-
ence in the width of the str. rad. was observed between both XPro1595 post-treatments
(p=0.899). These results indicate that pre-application of XPro1595 prevented a signif-
icant shrinkage of the str. rad. and that XPro1595 post-treatment attenuates further
shrinkage after SE induction.
Figure 5.15 Effect of XPro1595 treatment on the stratum radiatum 3 months after SE
induction. The thickness of the str. rad. is maintained in the XPro Prev condition. XPro1595 given
after SE induction is attenuating the shrinkage and efficiently peters out the progression. Asterisks
indicate significant difference from contralateral hippocampus. Diamonds point out significant difference
from another treated group.
Table 5.9 Stratum radiatum 3 months after SE induction
hippocampal sham KA-only XPro Prev XPro Resc XPro Chronic
side width in µm width in µm width in µm width in µm width in µm
contralateral 226 ± 10 176 ± 13 208 ± 21 191 ± 10 197 ± 14
ipsilateral 213 ± 4 46 ± 13 216 ± 7 117 ± 41 113 ± 14
t-test p=0.899 p=0.001* p=0.889 p=0.001* p=0.001*
In conclusion, the administration of XPro1595 before SE induction prevented the hip-
pocampal sclerosis in the KA-induced mouse model of TLE. Notably, administering
XPro1595 after SE induction also attenuated the hippocampal sclerosis.
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Figure 5.16 Effect of XPro1595 treatment on SE-induced hippocampal alterations. Immunhistochemical stainings in the hip-
pocampus in sham, KA-only, XPro Prev, XPro Resc and XPro Chronic animals 3 months after SE induction. KA-only (B2): Hippocampal
sclerosis is very prominent in the chronic phase, characterised by pyramidal neuronal loss in the CA1 region (white arrow), a shrinkage of
the str. rad. (red box), and heavily dispersed granule cell layer (yellow arrow). XPro Prev (C2): Animals showed no significant loss of
pyramidal neurons in the CA1 (white arrow). Furthermore, neither the width of the str. rad. was altered (red box) nor the granule cell
layer was dispersed (yellow arrow), indicating that XPro1595 pre-treatment prevented the development of hippocampal sclerosis completely.
XPro Resc (D2): Animals showed significantly less loss of pyramidal neurons in the CA1 (white arrow) compared with KA-only animals.
Neither the str. rad. was altered (red box) nor the granule cell layer was dispersed (yellow arrow), indicating that XPro1595 treatment after
SE rescued the development of hippocampal sclerosis. XPro Chronic (E2): Animals showed significant loss of pyramidal neurons in the
CA1 (white arrow). The str. rad. was significantly less shrunken (red box) compared with KA-only animals and the granule cell layer was
not dispersed (yellow arrow), indicating that XPro1595 therapeutical treatment salvages the development of hippocampal sclerosis. Scale
bar = 0.1 mm
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5.6.3 Astrocytic coupling is preserved by XPro1595
Astrocytic coupling is maintaining the homoeostasis of metabolites and ions in the brain.
The loss of GJC between astrocytes also plays an important role in the development of
epilepsy. An impairment of the astrocytic coupling strength by a reduction, contributes
to the development and progression of TLE as recently reported (Bedner et al., 2015).
Therefore, we studied the extent of coupling in animals treated with XPro1595 and KA-
only.
To compare the loss of astrocytic GJC on the ipsilateral hippocampus between KA-only
injected, XPro Prev and XPro Resc condition, three time points were chosen: 4 hrs
after KA injection representing the GJC at the beginning of the SE, 3 days after KA
injection representing the latent phase and 3 months after KA injection were chosen to
represent the GJC in the chronic phase of TLE. In Fig. 5.17 only the ipsilateral astrocytic
coupling strength is depicted (contralateral is shown as dashed line). At 4 hrs after SE
induction no significant difference between the number of biocytin positive astrocytes of
KA-only compared with XPro Prev is observed on the ipsilateral hippocampus (p=0.1).
In the latent phase 3 days after SE, both XPro conditions were signficantly altered
compared with KA-only ipsilateral side (KA-only vs. Prev p=0.007#, KA-only vs.
Resc p=0.017#). The same revealed for the chronic phase (KA-only vs. both XPro
conditions p=0.001#).
In summary, XPro1595 treatment before and after SE induction was able to prevent or
restore the gap junction coupling.
Figure 5.17 The effect of XPro1595 treatment on the SE-induced astrocytic uncoupling.
Summary of mean values of astrocytic GJC in dorsal slices of the ipsilateral hippocampus, expressed as
percentage of the number on the contralateral side. Contra- and ipsilateral measurements were always
conducted in the same slice. Coupling analysis was investigated at the time points 4 hpi, 3 dpi and 3
mpi in KA-only, XPro Prev and XPro Resc injected animals (contralateral vs. ipsilateral). Number
in bars indicate the number of slices and in brackets the number of investigated animals is displayed.
Asterisks indicate significant difference from contralateral hippocampus. Diamonds point out significant
difference from another treated group.
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5.7 Mechanistic effect of XPro1595
5.7.1 Incubation of hippocampal slices from wildtype mice with
TNF-α
To clarify the impact of TNF-α on astrocytic gap junction coupling we incubated acute
brain slices in situ from WT animals with TNF-α [10 ng/ml]. After 1 hr incubation
time patch-clamp recordings were started and after 5 hrs incubation time measurements
were terminated. Potential time dependent changes in the GJC were statistically tested
by grouping the slices into time frames; group I incubation time from 1-2 hrs, group
II incubation time 2-3 hrs, group III incubation time 3-4 hrs and group IV incubation
time 4-5 hrs incubation time. No significant alterations were detected (p-values between
0.81-0.89). We found no significant difference between the contralateral and ipsilateral
side (220 ± 54.4 vs. 253 ± 63.8 biocytin positive cells, p=0.537, n=11 slices from 3
animals).
In conclusion, these data show that solTNF-α alone is not able to cause a reduction in
astrocytic coupling strength, whereas a co-incubation with IL-1β does. Alternatively, a
secondary unknown released molecule might be needed to induce astrocytic uncoupling.
5.7.2 TNFR1 KO in KA-only induced TLE
EEG recording
All TNFR1 KO animals injected with KA-only developed SE. The SE started immedi-
ately after KA injection and was followed by the latent phase of 10.5 ± 3.3 days with no
seizure activity. The latent period was significantly longer in TNFR1 KO mice than in
KA-only animals (p=0.011*). For seizure activity monitoring, we recorded 4 animals up
to 3 months post SE induction. TNFR1 KO animals displayed significant less secondary
generalised spontaneous seizures compared with KA-only animals, 1 month (p=0.004*)
until 3 months (p=0.019*) after SE induction. The seizure activity is shown in table 5.10
and in Fig. 5.18b. Video-monitoring analysis showed that spontaneous electrographic
seizures were always accompanied by behavioural tonic-clonic convulsions.
Unchanged astrocytic coupling strength
To examine, which influence the TNFR1 signalling cascade has on the astrocytic GJC we
injected KA intracortically in TNFR1 KO animals. Four hours later the biocytin tracer
spread assay was performed to access coupling efficiency in the dorsal hippocampus.
We found no significant difference between the contralateral and ipsilateral side (171 ±
23.5 vs. 167 ± 22.5 biocytin positive cells, p=0.822, n=11 slices from 3 animals) (Fig.
5.18a).
These data indicate that the changes in astrocytic GJC are related to the TNFR1
signalling cascade.
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Table 5.10 Mean values of seizure activity in KA-only and TNFR1 KO animals
week KA-only TNFR1 KO statistical
after SE mean ± SD n mean ± SD n t-test
1 0.47 ± 0.31 4 0.14 ± 0.29 4 p=0.166
2 1.89 ± 0.80 4 0.36 ± 0.38 4 p=0.013*
3 1.75 ± 1.11 4 0.71 ± 0.81 4 p=0.181
4 2.86 ± 0.76 3 0.43 ± 0.55 4 p=0.004*
8 4.82 ± 2.15 6 0.18 ± 0.36 4 p=0.003*
12 4.99 ± 3.26 6 0.14 ± 0.29 4 p=0.019*
(a) (b)
Figure 5.18 TNFR1 KO mice in experimentally induced TLE. (a) In TNFR1 KO animals no
reduction of astrocytic coupling occurs 4 hrs after KA injection (c=contralateral, i=ipsilateral). (b)
Animals lacking the TNFR1 show almost complete lack of secondary generalised spontaneous seizure
compared with KA-only animals in the chronic phase of epilepsy. Asterisks indicate significant difference
from another treated group.
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Proinflammatory cytokines, such as TNF-α and IL-1β play an important role in neu-
rodegenerative diseases. In epilepsy they activate glial cells, which boost the cytokine
production. Cytokine release by glial cells contributes to the development and progres-
sion of epileptogenesis and the long-term manifestation of the disorder. Therefore, the
use of antiinflammatory drugs might be helpful to attenuate the development of epilep-
togenesis.
As several studies found increased levels of IL-1β in epilepsy (Rizzi et al., 2003; Vez-
zani et al., 2002; Balosso et al., 2008) the drug Anakinra, an IL-1R1 antagonist, was
tested for its anticonvulsant effect in vivo (Vezzani et al., 2000). The authors suggested
that an imbalance between IL-1β and its naturally occurring receptor antagonist IL-1Ra
contributes to seizure generalisation. If IL-1β is more present than IL-1Ra, IL-1β en-
hances NMDAR function by activating the Src tyrosine kinase, which phosphorylates
the NR2A/B subunit leading to subsequent increased Ca2+ influx and may contribute
glutamate-mediated neurodegeneration (Viviani et al., 2003). That is why VX-765, a
selective inhibitor of interleukin-1 converting enzyme (ICE), which cleaves IL-1β into
its active mature form, was shown to possess anticonvulsive effects in experimental ani-
mal models of epilepsy (Maroso et al., 2011; Ravizza et al., 2006). Moreover, a clinical
research was investigated by the company Vertex Pharmaceuticals Incorporated, which
was however stopped at clinical phase 2b, the dose finding phase (Vertex Pharmaceu-
ticals Incorporated, 2011). No reason for this early termination is officially available
by the manufacturer, but as it was stopped in the dose-finding phase, one can assume
that the inhibition of IL-1β production had too little effect on the outcome in epilep-
tic patients. The reason might be that still several other cytokines are able to induce
seizure generalisation. Especially, TNF-α has been shown to promote epileptogenesis,
as it shares common downstream signalling pathways with IL-1β, like the NFκB cas-
cade, and is able to induce its own expression (Chu, 2013; Philip and Epstein, 1986;
O’Neill and Bowie, 2007; Smolen and Steiner, 2003). Additionally, several studies have
reported a proconvulsive role of the solTNF-α/TNFR1 signalling (Balosso et al., 2005;
Weinberg et al., 2013) whereas drugs like etanercept and lenercept (binding both TNF-α
ligand forms) showed no improvement or even caused severe side effects, such as sepsis,
early septic shock, RA and MS (Kontermann et al., 2009; Sicotte and Voskuhl, 2001;
Slifman et al., 2003; Shakoor et al., 2002). Therefore, inhibiting only the solTNF-α form
seems to be a promising target for the treatment of epilepsy.
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6.1 XPro1595 prevents the development of
experimental TLE
In our animal model for MTLE-HS we could show that the application of solTNF-α
inhibitor XPro1595 prevented or even restored the astrocytic GJC. Thus, we could re-
duce significantly seizure activity, which is a clinical parameter and read out for the
efficiency of a therapeutical drug. Additionally, we could show that XPro1595 adminis-
tration attenuated the development of HS in the TLE model. These results highlight the
importance of astrocytic GJC on the initiation and development of MTLE: if coupling
remains functionally, the seizure activity and HS are significantly reduced.
The biggest effect was obtained when XPro1595 was given before the induction of SE
(XPro Prev), indicating that the inhibition of solTNF-α significantly prevented the
loss of astrocytic GJC and consequently the development of seizures and MTLE-HS.
We assume that XPro1595 administration prior to SE-induced epilepsy, immediately
binds the microglial released solTNF-α, which is induced by KA injection (see Fig.
6.1b). Therefore, XPro1595 prevents solTNF-α to bind its astrocytic TNFR1, which
is expressed during SE. Since no solTNF-α/TNFR1 signalling occurs, we suggest that
the phosphorylation-induced astrocytic uncoupling is prevented. Moreover, since the
solTNF-α/TNFR1 complex is not internalised, further gene expression and production
of TNF-α via NFκB pathway does not occur. This prevents a second wave of TNF-α
release from astrocytes. Since XPro1595 has no effect on the release of microglial IL-1β,
which is also released after the KA injection, IL-1β might bind to astrocytic and neuronal
IL-1R1. As Ravizza et al. (2008) found increased IL-1R1 expression after KA-induced
SE on astrocytes, it might be possible that increased IL-1R1 expression via intracellular
signalling cascades, such as NFκB pathway, could also activate nuclear gene expression
and subsequently cause de novo synthesis of TNF-α. Since the astrocytic de novo syn-
thesised and released TNF-α is depleted by XPro1595, activation of solTNF-α/TNFR1
signalling cascade-induced astrocytic uncoupling or release of secondary cytokine waves
are consequently prevented. In the XPro Prev condition, only a slightly decreased num-
ber of pyramidal neurons on the ipsilateral hippocampus was obtained, compared with
the contralateral side. This might be a direct effect of injected KA, which is well known
to induce neuronal death within the first 24 hrs after injection (Doble, 1999). Notably,
less neuronal cell death was also observed in the XPro Resc treatment compared with
KA-only animals, when we applied XPro1595 4 hrs, 3 and 6 days after SE. In contrast,
when XPro1595 was given after the first spontaneous generalised seizure (XPro Chronic),
it had no effect on the extent of neurodegeneration of pyramidal neurons in the CA1
region.
Four hours after SE induction, we found a significant loss of astrocytic GJC in KA-only
animals and from ELISA we know that TNF-α was significantly elevated at this time
point. One day after SE induction TNF-α was decreased, but still significantly expressed
above basal level on the ipsilateral hippocampus and GJC was also impaired. As we also
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could show that TNF-α levels are more strongly upregulated than IL-1β in our animal
model, these results indicate that the solTNF-α is mainly responsible for the loss of as-
trocytic GJC. It was shown by Bedner et al. (2015) that the loss of astrocytic GJC was
already present 4 hrs after SE induction, whereas neuronal death started 6 hrs after SE.
This result clearly demonstrated that impairment of astrocytic GJC is a causal event,
while neuronal death and generalised spontaneous seizures are merely consequences. An
unpublished study from our group by Deshpande et al. (2018) found that XPro1595
prevented the cytokine-induced phosphorylation of the Cx43 C-terminus at S262 and
the consequential loss of coupling in situ 4 hrs after SE induction. They concluded that
”TNF-α and/or IL-1β induced phosphorylation of S262 causes or critically contributes
to astrocytic uncoupling” in the MTLE model. We could demonstrate in our XPro Prev
animals, that even a massive TNF-α release 4 hrs after SE induction did not impair GJC
due to the inhibition of solTNF-α by XPro1595. That demonstrates, that XPro1595 ad-
ministration prevented the loss of astrocytic GJC in vivo. Moreover, XPro Prev animals
showed no loss of astrocytic GJC in the latent and chronic phase, consequentially no
generalised spontaneous seizures developed and almost no HS was found 3 months after
SE induction (Fig. 6.1b). This provides further evidence that astrocytic GJC has an
initiating role in the development and progression of TLE.
The administration of XPro1595 in vivo after SE was able to rescue and restore astro-
cytic GJC in the latent and chronic phase. We believe that this findings result from the
fact that XPro1595 binds the second wave of TNF-α release by astrocytes, thereby in-
hibiting TNFR1-induced astrocytic uncoupling. Consequently, the functional astrocytic
GJC allows an equal distribution of K+ and glutamate via the astrocytic syncytium,
which reduces neuronal hyperexcitability and decreases seizure activity, as we have also
observed it 2-3 months after SE induction. Furthermore, the development of HS was
attenuated in the long-term (Fig. 6.1c). All results from this study are depicted in
a summarising figure, including our suggested mechanism of action of XPro1595 (Fig.
6.1b,c).
In conclusion, the inhibition of solTNF-α restored the astrocytic GJC in TLE and at-
tentuated the clinical progression/manifestation of the disorder. Therefore, testing com-
pounds that improve Cx43 gap junction-mediated coupling between astrocytes in the
brain would be the next promising step in the development of new AEDs (see chapter
8).
6.2 Glial cells release cytokines in two waves
It is still unclear whether astrocytes or rather microglial cells are the major solTNF-α
releasing cells.
As microglial cells, which belong to the innate immune system, are thought to act first
by releasing cytokines, it might be that a ”1st wave” of microglial TNF-α binds to neigh-
bouring cells like neurons and astrocyte (Vezzani et al., 2002; Wang et al., 2015). When
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we give XPro1595 before the SE induction, this first wave of TNF-α is inhibited and only
IL-1β from microglia might be able to bind astrocytic and neuronal IL-1R1. The IL-1R1
signalling involves the activation of NFκB, which triggers the transcription of TNF-α
and IL-1β in neurons and astrocytes. The production and release of a ”2nd wave” of
both cytokines from astrocytes might act as a positive feedback loop, strengthening the
inflammatory processes (Novrup et al., 2014). As under our experimental conditions
the released TNF-α is immediately bound by XPro1595, only IL-1β persists and binds
to its receptor on astrocytes again (Fig. 6.1b). Astrocytes are thought to be the main
cell influcencing the proinflammatory cytokine microenvironment at this phase (Vezzani
and Baram, 2007). To understand which part and impact microglial cells and/or as-
trocytes have in the acute phase of epilepsy, studies investigating cell-specific knockout
animals should be done to better understand how specifically they contribute to the neu-
roinflammatory signalling. Furthermore, studying other cytokine-producing cells, such
as invading macrophages and T-cells, could help to understand better the activated
pathways and contribution of the adaptive immune system leading to epileptogenesis.
6.3 Alterations in coupling are TNFR1-mediated
IL-1β was found to cause reduction in astrocytic GJC (Meˆme et al., 2006; Bedner et al.,
2015), which might explain the observed impaired coupling strength within the acute
phase after SE induction. As the IL-1R1 expression was found to decrease in astro-
cytes after the acute phase of epileptogenesis (Vezzani et al., 2002; Balosso et al., 2008),
the IL-1β/IL-1R1 feedback loop would stop by itself. Our results support this idea, as
IL-1β levels were found to be significantly reduced in KA-only animals after the acute
phase of SE induction and even the astrocytic GJC was found to be unaltered again
in the latent phase at day 5 post KA injection. XPro Prev animals display unaltered
astrocytic GJC 3 days after SE induction, whereas GJC is still impaired in KA-only
animals at this time point. Hence, IL-1β alone cannot be the only reason for impaired
coupling as we found no reduction in XPro Prev animals in the acute phase. This indi-
cates that solTNF-α must also have an influence on the impairment of astrocytic GJC.
Indeed, TNFR1 KO mice displayed no seizure-induced reduction in GJC, indicating
that TNFR1 contributes to the uncoupling. These animals were less prone to generate
secondary generalised spontaneous seizures, assuming that TNFR1 has a proconvulsive
role in the development of TLE. This is in line with previously published studies from
Balosso et al. (2005) and Weinberg et al. (2013), who also found a TNFR1-mediated
proconvulsive effect. To directly assess the influence of increased TNF-α levels on the
astrocytic coupling, we incubated acute brain slices from WT animals in ACSF solution
containing high concentration of TNF-α (400-fold higher than the values observed by
ELISA after SE induction) and found no impairment of astrocytic GJC. One explana-
tion could be that high TNF-α concentration activate TNFR2-mediated anticonvulsive
signalling cascade, due to its 30-fold higher dissociation rate of TNF/TNFR2 complex
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(Grell et al., 1998). Additionally, our immunohistochemical analysis indicated TNFR1
expression only in astrocytes in the str. rad. on ipsilateral hippocampus of KA-injected
mice 4 hrs after SE induction, but not in sham-injected animals (data not shown), in-
dicating that seizure activity causes an upregulation of TNFR1. That KA indeed is
able to induce receptor expression changes was already reported for TLR4 alterations in
astrocytes by Maroso et al. (2010).
Obviously, in addition to TNF-α, a second mediator is needed for the reduction of GJC.
This might be transiently present, such as IL-1β. There is some evidence that ”TNF-α
rarely induces apoptosis in the absence of a secondary signal” (Park and Bowers, 2010;
Chao et al., 1995) or that ”TNF-α and KA cooperate” to activate glial cells, which
then produce and release more TNF-α and glutamate, ”potentiated via a feedforward
cascade, and thereby perpetuating the process” (Hermann et al., 2001). This may be
another possible explanation for the lack of effect of TNF-α on GJC in situ, as KA
seems to induce TNFR1 expression on astrocytes in our MTLE mouse model or that
KA-induced hyperactivity is causing an TNFR1 upregulation.
Recently, our group Deshpande et al. (2018) incubated acute brain slices in situ with
IL-1β and TNF-α and found unaltered protein expression levels of Cx43 and Cx30 4
hrs after SE, a finding that differs from previous studies in cortical astrocyte cultures
(Meˆme et al., 2006; Zhang et al., 2015). Desphande et al. (2018) found strong evidence
that phosphorylation of S262 in the C-terminal tail of Cx43 accounts for an immedi-
ate loss of astrocytic GJC. S262 is phosphorylated by MAPKs, resulting in decreased
open probability and a rapid internalisation of Cx43 GJ channels (Lampe et al., 1998;
Thevenin et al., 2013). A loss of astrocytic GJC was prevented by XPro1595 co-
incubation in situ. IL-1β and TNF-α can activate the MAPK pathway, which leads
to the translocation of transcriptional factor AP-1 from the cytoplasm into the nucleus.
In the nucleus AP-1 activates nuclear gene expression, which also includes the transcrip-
tion of both inducer-cytokines (Smolen and Steiner, 2003; Takada and Aggarwal, 2004).
In cultured astrocytes, cytokine-mediated uncoupling was prevented by application of
a MAPK inhibitor, indicating that the loss of coupling was a consequence of MAPK
activation (Retamal et al., 2007).
From our results, we know that TNF-α via TNFR1 signalling is able to cause astrocytic
uncoupling, but we also found that TNF-α release only is not sufficient enough to cause
a loss of astrocytic GJC. We suggest, that together with TNF-α another mediator is
needed and both molecules induce long-term activation of glial cells or neuronal cell
death. Allan et al. (2005) showed that ”a solo-application of IL-1β into the brain of
WT animals failed to cause detectable neuronal injury, suggesting that co-administration
with other cytokines or molecules leads to greater impact of neurotoxicity”.
Taken together, TNF-α rather initiates, enhances or prolongs the pathophysiological
changes together with a secondary mediator, such as KA, IL-1β or a so far unknown
molecule. Notably, TNF-α seems to be a key player in the development and progres-
sion/manifestation of TLE. Therefore, XPro1595 administration is effective in attenu-
ating epileptogenesis in our model.
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6.4 Effects of XPro1595 in neuroinflammation-induced
diseases
We could show in our mouse model of MTLE-HS, that the preservation of astrocytic GJC
due to XPro1595 administration significantly reduced generalised spontaneous seizures
and attenuated HS in the long-term. We suggest, that beside its impact on preserv-
ing astrocytic GJC, XPro1595 might secondaryly decrease the inflammation response
by glial cells, which might contribute by cytokine production and release to neuronal
hyperactivity and/or morphological alterations, like HS in TLE.
As TNF-α plays an important role in several other neuroinflammation-induced diseases,
XPro1595 has been shown to have secondaryly beneficial effects in experimental models
of spinal cord injury (Novrup et al., 2014), multiple sclerosis (Karamita et al., 2017),
Alzheimer’s disease (MacPherson et al., 2017; Cavanagh et al., 2016), Parkinson’s dis-
ease (Barnum et al., 2014), Huntington’s disease (Hsiao et al., 2014) and limbic epilepsy
(Patel et al., 2017).
XPro1595 was shown to prevent the induction of phenotypical transformation of mi-
croglial cells into an activated state (Karamita et al., 2017; Novrup et al., 2014) by
local inhibition of solTNF-α and to reduce the immune response by blocking the in-
vasion of early innate immune cells, such as infiltrating macrophages, monocytes and
the adaptive immune response by reducing the number of activated CD4+ T-cells and a
CD11+ immune cell population (Novrup et al., 2014; MacPherson et al., 2017). These
results suggest that XPro1595 might be able to hinder immune cells crossing the BBB
and the consequential upregulation of inflammation and neuronal damage in the brain
tissue (Rezai-Zadeh et al., 2009; MacPherson et al., 2017). That XPro1595 reduces
neuronal damage or even prevented the loss of dopaminergic neurons in the substantia
nigra was shown in experimental models of SCI (Novrup et al., 2014), PD (Barnum
et al., 2014) and HD (Hsiao et al., 2014). Also our data show a significant attenua-
tion of neuronal loss in the hippocampus after XPro1595 administration in experimen-
tal TLE. This finding suggests that the inhibition of solTNF-α prevents secondarily
cytokine-induced neuronal death by functional astroyctic GJC, which maintains the ho-
moeostasis of metabolites and ions during seizure activity. Another possibility might be
that XPro1595 inhibits astrocytic TNF-α glutamate release causing a spillover, which
contributes to neuronal hyperexcitability and might lead to the trafficking of neuronal
NMDAR/AMPARs. That XPro1595 is able to rescue hyperexcitability of glutamatergic
synapses was demonstrateted in two transgenic mouse models for AD (Cavanagh et al.,
2016; MacPherson et al., 2017). In a mouse model of SCI Novrup et al. (2014) found
that XPro1595 even improved functional recovery, such as remyelination, and showed an
upregulation of TLR4 protein levels, which promotes the remyelination by proliferating
oligodendrocytes (Schonberg et al., 2007). It is well known, that TLR4 is activated
by damage associated molecular pattern molecules, such as HMGB1, in the presence
of TNF-α and IL-1β, which contributes to seizure generation (Vezzani et al., 2008;
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Maroso et al., 2010). Therefore, it would be interesting to investigate the effect of
XPro1595 on the HMGB1-TLR4 mediated activation of astrocytes. As our group has
previously shown that TLR4 KO mice showed no loss of astrocytic GJC 1 day after SE
induction (Bedner et al., 2015), it would be interesting to investigate seizure activity in
these animals in the acute phase in our TLE model.
An increasing number of recent studies show that distinguishing between the two TNF-
α forms and their induced receptor signalling pathways, is essential for the therapeutic
outcome. The study by Novrup et al. (2014) even showed that the inhibition of both
TNF-α forms by etanercept in a model of SCI had no effect, whereas the administration
of XPro1595 had a protective effect with regard to pathophysiological changes. They ob-
served a transient upregulation of TNFR2 protein levels after XPro1595 administration,
suggesting that XPro1595 also promotes the signalling via TNFR2 pathway, which is
well known for its function in neuroprotection and remyelination (Taoufik et al., 2011).
Enhanced TNFR2 signalling was shown to have anticonvulsant effect in epileptic ani-
mals (Balosso et al., 2013; Patel et al., 2017). We found in our KA model of TLE that
TNFR1 immunofluorescence is increased only in astrocytes in the acute phase. Other
studies report a downregulation of TNFR2 in neurons and absence in astrocytes (Balosso
et al., 2013; Weinberg et al., 2013). XPro1595 might also promote an upregulation of
TNFR2 expression in TLE, thus inhibiting the hyperexcitability. It would be interesting
to see, how the ratio of TNFR1 and TNFR2 changes under XPro1595 administration in
experimental TLE.
Interestingly, a recent study in a limbic epilepsy model by Patel et al. (2017) re-
ported that XPro1595 was ineffective in preventing seizures. These authors used an
infection-induced mouse model, in which mice were infected with the theiler’s murine
encephalomyelitis virus (TMEV) through intracortical injection into the right hemi-
sphere. The animals showed seizures 3-8 days after infection and developed chronic
spontaneous seizures. The hippocampus displayed morphological changes, such as re-
active glia cells, loss of pyramidal neurons in CA1 and increased cytokine expression,
especially of proinflammatory cytokines IL-1β, TNF-α, interferon-γ (IFNγ) and of anti-
inflammatory cytokine IL-10. Beside that, the model displayed oxidative stress markers
and infiltrating macrophages in the first week after infection, which is thought to con-
tribute to the initiation and/or propagation of acute seizures in TMEV-induced limbic
epilepsy. Furthermore, they concluded from their data that the solTNF-α/TNFR1 sig-
nalling decreases the seizure threshold in limbic epilepsy by TNF-α-mediated AMPAR
trafficking. Suprisingly, they detected no significant differences in the GluA1 and GluA2
subunits of AMPARs between WT and TNFR2 KO animals, suggesting that the hyper-
excitability is not only based on AMPAR or depends on the regional variances of TNF-α
and TNFR1 expression.
The TMEV-induced limbic seizure mouse model shows many similarities of pathophysi-
ological changes compared with our KA model. Both display the development of HS and
seizure activity. However, the cytokine profile of the two animal models is very different.
Using the same ELISA kit as Patel et al. (2017), we found a significant increase in
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TNF-α levels compared with the non-injected control side, whereas Patel et al. (2017)
observed no significant increase in TNF-α compared with PBS-injected control mice 24
hrs after SE induction. As cytokine release is known to occur very early after the insult,
we measured cytokine levels within the first 24 hrs after SE induction and found the
highest levels of TNF-α and IL-1β after 4 hrs of SE induction. Both cytokines were sig-
nificantly reduced after 24 hrs in our mouse model. However, Patel et al. (2017) found
no significant changes of IL-1β, TNF-α, IFNγ, IL-10, IL-2 and IL-5 24 hrs after SE
induction, but a significant increase 5 days after TMEV-infection in their model. Com-
paring the absolute levels of TNF-α between the models, they already display differences
of cytokine expression 1 day after induction: Patel et al. (2017) measured 12-fold higher
basal TNF-α in PBS-injected control mice than we did. The TMEV-infected animals
showed 6-fold more TNF-α compared with our results from KA-injected animals.
Patel et al. (2017) injected XPro1595 (10 mg/kg s.c.) similarly to our treatment pro-
tocols. They tried several XPro1595 administration schemes: local administration into
the ventricles, XPro1595 injection before TMEV-infection (which is similar to our XPro
Prev condition) and they gave the first XPro1595 injection 2 hrs after TMEV-induced
SE followed by two additional injections at 3-days interval (which is similar to our XPro
Resc treatment). Despite that, Patel et al. (2017) never saw a beneficial effect on the
number of seizure activity 3-8 days after induction. In our model XPro1595 adminis-
tration before SE induction (XPro Prev) almost completely inhibited seizure activity
1 week after SE induction. The post-treatment condition XPro Resc received the first
injection 4 hrs after SE induction and XPro Chronic animals received the first XPro1595
injection after the first generalised spontaneous seizure, which is even much later com-
pared to the application scheme used by Patel et al. (2017) and, notably, we detected
a significant decrease in seizure activity in both post-treated conditions 2 and 3 months
after SE induction. Like Patel, we also measured increased TNF-α levels within the first
24 hrs after SE induction and did not see any significant reduction in seizure activity in
the first week after SE induction. Seizure activity was only significantly reduced in the
long-term. Thus, the seizure activity may not have been measured long enough to see
significant differences in the study by Patel et al. (2017). Therefore, it would be very
interesting to know whether in the TMEV-induced limbic epilepsy model the seizure
activity would be reduced in the long-term as well and whether HS would be also less
prominent, as it is the case in our study. These findings could help us to understand the
relationship between inflammation-induced mechanisms and the progression of epilepsy,
especially with regard to the loss of astrocytic GJC, reactive gliosis and neuronal cell
death.
Another interesting result from Patel et al. (2017) is the finding of significantly upreg-
ulated cytokines IL-2, IL-5 and IL-10 within the first week after induction. This result
indicates that the innate and adaptive immune system are closely linked in TLE. The
invasion of cells of the adaptive immune system into the brain plays an important role
in epileptogenesis. IL-2 activates T helper cells, which can recruit further cells of the
adaptive immune response, such as B lymphocytes, and induce IL-5 production (Malek
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and Castro, 2010). IL-5 enhances the immune response by stimulating B cells to pro-
duce antibodies (Takatsu, 2011). To avoid an overshoot of inflammation, T helper and
T regulatory cells (Tregs) produce IL-10, which acts as an antiinflammatory mediator
(Chaudhry et al., 2011; Ng et al., 2013). It would be interesting to see whether XPro1595
could prevent the response of the adaptive immune system by reducing or blocking the
innate immune response and therefore might be also able to prevent an infiltration of
immune cells into brain or the breakdown of BBB in epilepsy.
The elevation of proinflammatory cytokines, such as TNF-α and IL-1β, mainly influence
the development and progression of TLE. Especially a selective inhibition of solTNF-
α/TNFR1 signalling has the potential to modulate the immune response in the diseased
brain, as it attenuates neuroinflammation and prevents or dampens the progression of
the disease.
The development of selective inhibitors for the solTNF-α/TNFR1 cascade opens up new
possibilities in the field of antiinflammation. It gives us the possibility to investigate
TNF function and novel strategies in clinical approaches. Beside the dominant-negative
TNF mutants that exclusively bind to the ligand solTNF-α, inhibitors that selectively
bind to a TNFR1-domain, e.g. R1antTNF, DMS5540, TROS, ATROSAB, were de-
veloped (Kontermann et al., 2009; Fischer et al., 2015). The decision of using either
solTNF-α or TNFR1-domain inhibitors in diseases with pronounced elevated TNF-α
levels depends on the context. Arguments in favour of applying solTNF-α inhibitors
are that the local cross-signalling of the tmTNF-α form via TNFR1 has a protective ef-
fect in the immune response. It was shown that treated animals were protected against
viral and microbial infections and that the tmTNF-α/TNFR1 signalling promoted neu-
ronal survival (Zalevsky et al., 2007; Taoufik et al., 2008). Therefore, using TNFR1-
domain antagonists would inhibit these effects. An argument against the application of
solTNF-α inhibitors is that solTNF-α is not able anymore to induce TNFR2 signalling
in cells displaying high TNFR2 expression, such as Tregs cells, thus compromising the
adaptive immune modulatory response via TNFR2 (Chen and Oppenheim, 2011). An
advantage of TNFR1-domain antagonists is that the proinflammatory lymphotoxin-α
(formerly known as TNF-β) cannot bind to its receptor, contributing to inflamma-
tory diseases, like experimental allergic encephalomyelitis and RA (Suen et al., 1997;
Calmon-Hamaty et al., 2011).
For future clinial approaches, one can only speculate which antagonist application is
more beneficial or rather harmful. This aspect depends on the type of disease and its
inflammatory progression. Another recently published stragtegy is to artifically enhance
the protective function of the tmTNF/TNFR2 signalling pathway by using single chain
TNF ligands (Fischer et al., 2017).
Beside preserving astrocytic GJC via inhibiting solTNF-α, XPro1595 might secondaryly
modulate the expression and function of TNF-induced alterations of receptors, through
phosphorylation at the membrane (Viviani et al., 2007). In a study with TNF-deficient
astrocytes Santello et al. demonstrated that the administration of low picomolar amounts
of solTNF-α was sufficient to restore astrocytic gliotransmission in the DG (Santello et
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al., 2011). Under physiological conditions, local production of solTNF-α seems to rapidly
regulate the strength of synaptic connectivity and thereby influencing the neuronal net-
work (Probert, 2015). Elevated levels of proinflammatory cytokines in neurodegenerative
diseases, might further induce a loss of GABAergic neurons in the hippocampus, thereby
decreasing the seizure threshold (Samland et al., 2003). Beside a reduction in synaptic
inhibition, TNF-α enhances neuronal excitability by modulating NMDAR and AMPAR
(Balosso et al., 2009; Seifert et al., 2010). In limbic epilepsy the seizure threshold was
found to be reduced by solTNF-α/TNFR1-mediated alterations in AMPAR trafficking
(Patel et al., 2017). Hence, it would be interesting to see whether these mechanisms also
contribute to the observed XPro-induced reduction in seizure frequency in our model
of TLE. Nevertheless, XPro1595 preserves astrocytic GJC, and this seems to be the
primary reason why the seizure activity in our model is decreasing. That the admin-
istration of XPro1595 also attenuated the HS is a secondary finding, which could be
due to the effect that XPro1595 preserved the astrocytic GJC. Additionally, XPro1595
might have an influence on subordinate mechanisms of other cell types.
6.5 Antiinflammatory substances with potential clinical
relevance in TLE
Inflammation is an attractive target for treating epilepsy. On the one hand, that gives
various possibilities for the development of new drugs, targeting different mechanisms
and approaching different cell signalling pathways. On the other hand, it displays ex-
actly the difficulties, which arise when confronted with a great diversity. If an initial
insult activates the innate immune system, blocking the inflammatory cascade, such
as NFκB- and MAPK pathways could be beneficial. However, as signalling cross-talk
occurs new drugs need to be carefully designed with the following characteristics: i) spe-
cific inhibition of proinflammatory cascades, while sparing antiinflammatory signalling,
which contributes to cell protection or repair of neuronal circuits (Dedeurwaerdere et al.,
2012), ii) avoidance of cascade cross-talk and iii) drug accessibility. The drugs should
be designed with appropriate brain penetration properties if it should be used for fu-
ture clinical approaches with systemic administration. Furthermore, the time course of
epileptogenesis displays different immune responses. If a drug is intended to be admin-
istered in the acute phase, rather innate immune signalling should be targeted, whereas
in the latent or chronic phase the adaptive immune response is probably a more relevant
target.
The treatment with minocycline, an antibiotics, which has been shown to have neuronal
protection, could prevent microglial activation after KA-induced SE (Abraham et al.,
2012). In a viral-like CNS inflammation model, minocycline suppressed the increased
seizure susceptibility or reduced the number of seizures in mice probably by lowering
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the IL-1β levels by inhibiting the IL-1β converting enzyme (ICE) (Galic et al., 2009;
Libbey et al., 2011). Targeting the IL-1β system by inhibiting ICE with the compo-
nent VX-765 showed strong anticonvulsant effects in KA models of epilepsy and seemed
to be a promising target, but clinical trials were terminated in phase 2b (Ravizza and
Vezzani, 2006; Maroso et al., 2011; Vertex Pharmaceuticals Incorporated, 2011). An-
other study showed that the combination of Anakinra and VX-765 in two rat models of
TLE was ineffective in neuroprotection and did not prevent the development of sponta-
neous seizures (Noe et al., 2013). Targeting other proinflammatory cytokines, such as
TNF-α signalling by administering specific inhibitors of solTNF-α or blockers selectively
binding to a TNFR1-domain, has shown to be more promising in animal models. The
small molecule Minozac, a selective inhibitor of proinflammatory cytokine production
prevented reactive gliosis and the increase of proinflammatory cytokines, like IL-1β, IL-6
and TNF-α in the hippocampus (Somera-Molina et al., 2007; Chrzaszcz et al., 2010).
The advantage of Minozac is that it was shown to penetrate the BBB (Hu et al., 2007;
Lloyd et al., 2008).
Leukocyte migration modifies the permeability of BBB in inflammatory disorders and
BBB failure has been shown to contribute to the onset of epilepsy (Marchi et al., 2007;
Larochelle et al., 2011). Conversely, epileptic seizures were shown to further destroy
the BBB and a disrupted BBB allows further massive leukocytes infiltration into the
brain (Marchi et al., 2007; Daneman and Prat, 2015). Beside leukocyte invasion also
an influx of ions, serum proteins and other adaptive immune cells occur, which may
enhance seizure activity. Blocking the leukocyte-endothelial interaction via antibod-
ies, which inhibit the vascular cell adhesion protein1 or endothelial ligand intercellular
adhesion molecule1, has been shown to reduce the seizure frequency in a pilocarpine-
induced mouse model of epilepsy and in MS patients with epilepsy (Fabene et al., 2008;
Sotgiu et al., 2010). Therefore, preventing leukocyte penetration into the brain might
be a useful therapeutical target.
Another therapeutical target is the cyclooxygenase (COX) inhibition. COX-2 is primar-
ily activated by inflammation. Administration of a selective COX-2 inhibitor (Celecoxib)
or selective inhibitor for COX-1 (SC-560) as well as the application of non selective COX
inhibitors (Aspirin, Indomethacine) have been reported to reduce the seizure frequency
in pilocarpine-induced rat model of TLE (Jung et al., 2006; Tanaka et al., 2009) and
even to attenuate the hippocampal neuronal loss, GCD and mossy fiber sprouting (Ma
et al., 2012). Those studies assume that cyclooxygenase enzymes, derived from neurons
and microglial cells, might also affect the development of seizures beside proinflamma-
tory cytokines (Mirrione and Tsirka, 2011).
As mentioned above, several studies have reported that various ways of antiinflammatory
treatment improve epileptogenesis in different animal models of epilepsy. That empha-
sises the importance of blocking inflammatory signalling as a treatment for epilepsy.
Various signalling casacades are activated in the development of epilepsy, leading to
an up- and/or downregulation of protein levels, receptor expression changes, molecule-
and ions alterations influencing the homoeostasis in a bunch of cell-cell interactions and
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their networks. Therefore, it is highly important that newly developed antiinflamma-
tory drugs are tested in an animal model that closely mimicks functional and structural
changes of human MTLE-HS. The intracortical KA model displays similar character-
istics in the chronic phase like observed in hippocampal tissue resected from epileptic
patients (Bedner et al., 2015). Thus, this model seems to be suitable for clarifying
the underlying mechanisms initiating the human disease and might serve as a model of
pharmacoresistance at the late stage. We could show that XPro1595 was able to atten-
uate the hallmarks of sclerosis and to reduce the seizure frequency in our model, even
when the first administration occured after the first spontaneous generalised seizure.
Our results indicate that XPro1595 in vivo is successfully dampening the progression of
epileptogenesis by restoring functionality of astrocytic GJC, thus i) further proconvulsive
effects were prevented and seizure activity was significantly reduced and ii) morpholog-
ical changes like HS were attenuated. Importantly, XPro1595 has been shown to cross
the BBB and to have no severe side effects in animals models of neurodegenerative dis-
eases.
In conclusion, XPro1595 is a highly potent drug for clinical approaches as it dampens
the neuroinflammational processes in the development of epilepsy and is easily admin-
istered systemically. In further clinical trials especially the dose-finding phase will be
important, in which the optimum dose at which the drug shows biological activity with
minimal side-effects, is studied.
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Figure 6.1 Potential mechanism of XPro1595: (a) In WT animals basal concentration of cytokines are expressed mainly by microglial
cells. After KA-injection, SE-induced cytokine levels increase (primary TNF-α), TNFR1 is present on astrocytes and GJC is impaired. In
the acute phase astrocytes produce and release TNF-α (2nd cytokine wave), followed by the latent phase. A loss of GJC is observed in
the chronic phase and generalised spontaneous seizures occur. (b) XPro1595 administration before SE-induced epilepsy binds immediately
microglial released TNF-α after KA injection. No TNF/TNFR1 signalling casacade is activated and astrocytic GJC preserved. No
generalised spontaneous seizures occur. (c) XPro1595 administration after SE-induced epilepsy reduces further TNF-α production and
release by astrocytes, thus TNFR1-mediated uncoupling is inhibited. Restoring astrocytic GJC reduces significantly seizure activity and
attenuates HS in TLE in the long-term.
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Antiepileptic therapies are mainly based on drugs which target neuronal function. One
third of epileptic patients do not respond adequately to these treatments and, impor-
tantly, all available drugs merely suppress seizures without curing the underlying disor-
der. Consequentially, new strategies for the development of antiepileptogenic drugs are
urgently needed.
Brain inflammation contributes to a loss of gap junction-mediated coupling between as-
trocytes, which is a causal event in the development of temporal lobe epilepsy (TLE).
In a first step we assessed the effect of XPro1595 (a selective inhibitor of soluble TNF-
α) and Anakinra (IL-1R antagonist) in situ in acute brain slices from epileptic mice
and found that astrocytic coupling was restored. To investigate this in more detail, we
checked the cytokine levels in the intracortical kainate (KA) model using ELISA. The
results show elevated TNF-α levels immediately after KA-induced status epilepticus
(SE), whereas IL-1β was less prominent. This finding prompted us to assess the effect of
solTNF-α/TNFR1 signalling cascade on astrocytic coupling. Hence, we investigated the
effect of XPro1595 i.p. injection on astrocytic coupling and the development of TLE.
The results show that XPro1595 given in vivo prior to KA injection prevented the loss
of astrocytic gap junction coupling and thus the development of generalised spontaneous
seizures and hippocampal sclerosis (HS) were prevented.
Treatment with XPro1595 in vivo after KA injection rescued astrocytic coupling, signif-
icantly decreased chronic seizure frequency in the long-term and attenuated HS-specific
morphological alterations.
To confirm the effect of solTNF-α/TNFR1 signalling cascade on astrocytic coupling, we
used transgenic TNFR1 KO animals in our epilepsy model. We could show that TNFR1
KO astrocytic coupling was unaltered after SE-induction, indicating that TNFR1 acti-
vation regulates astrocytic coupling strength. Furthermore, these animals showed signif-
icantly less seizure activity, demonstrating the importance of astrocytic coupling on the
progression of TLE. However, incubation of acute brain slices from wildtype mice with
TNF-α in situ revealed no impaired astrocytic coupling. Therefore, we suggest that
a second mediator, like IL-1β or a yet unknown molecule, might be needed to induce
astrocytic uncoupling.
In conclusion, this study demonstrates that solTNF-α/TNFR1 mediates astrocytic un-
coupling and plays a key role in the development of TLE-HS. Rescuing astrocytic cou-
pling might represent a new strategy to develop antiepileptogenic therapies. The present
project elucidated the therapeutic potential of targeting astrocytic proteins in epilepsy
and also shed further light on the mechanisms underlying the disorder.
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In the present study, the most exciting discovery is that the preservation of astrocytic
GJC (by inhibiting soluble TNF-α) even after the first generalised spontaneous seizure,
is able to decrease epileptic seizures and to attenuate the hallmarks of sclerosis.
Therefore, the development of Cx43 gap junction activators or enhancers should be con-
sidered as potential new antiepileptic drugs. Such compounds would represent a proof-
of-concept in terms of their antiepileptogenic potential as Cx43 enhancers. Activators
for Cx43 gap junctions have already been developed for the treatment of reperfusion
injury after acute myocardial infarction. Danegaptide (ZP1609, from Zealand Pharma)
is a dipeptide that increases gap junction conductance in the heart by modulating Cx43
phosphorylation. In an animal model, Danegaptide was able to prevent atrial fibrilla-
tion and was tested in the clinical phase 2 for its treatment of reperfusion injury after
myocardial infarction. The study was terminated prematurely as there was no signifi-
cant effect. The advantage of Danegaptide, compared to other Cx43 activators such as
Rotigaptide or PQ7, is its oral bioavailability and its ability to penetrate into the mouse
brain (Wang et al., 2018; Shishido et al., 2013). However, Danegaptide and other Cx43
enhancers are still far from being used as an ideal drug for preserving astrocytic gap
junctional coupling in the epileptic brain. For the use of Cx43 activators, with regard
to their antiepileptogenic potential, the compounds would have to be further devel-
oped. To avoid undesirable side effects, Cx43 activators should exclusively address Cx43
GJ-mediated coupling between astrocytes in the brain. In addition, such compounds
must be able to penetrate the BBB in order to maintain or improve GJC. To deter-
mine whether the identified Cx43 activators act through proinflammatory cytokines and
their signalling pathways, acute brain slices could be incubated with proinflammatory
molecules such as IL-1β and TNF-α in the presence and absence of the Cx43 activators
and the consequences on astrocytic GJC assessed. Therefore, testing Cx43 astrocytic
GJC enhancers for their antiepileptogenic potential and the mechanism of action in our
KA model of TLE, as well as in acute hippocampal specimen, surgically resected from
intractable MTLE patients, would be the next promising step towards a new strategy
for the development of new AEDs.
Furthermore, to gain a better understanding on the role of XPro1595 and its protect-
ing/ rescuing effect on astrocytic coupling, it would be worthwhile to investigate next
whether XPro1595 exerts its antiepileptogenic effect exclusively by preserving the cou-
pling. To answer this question, transgenic mice devoid of astrocytic GJC (Cx30−/−;
Cx43fl/fl hGFAP-Cre mice) could be subjected to the KA model of TLE. If astrocytic
coupling is the target of XPro1595 action, the substance should be ineffective in these
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transgenic animals.
Seizures disrupt the BBB and cause albumin leakage into the brain parenchyma (Ivens
et al., 2007; Van Vliet et al., 2012). Extravascular albumin decreases the gap junctional
coupling in astrocytes (Braganza et al., 2012). The astrocytic coupling experiments
performed under XPro1595 administration in the present study never showed altered
GJC. It might be interesting to analyse the influence of XPro1595 on BBB disruption
in the hippocampus. Albumin-bound Evans blue enters the CNS when the BBB is
compromised. Thus, no extravasation of Evans blue or immunohistochemically detected
albumin should be detectable if XPro1595 prevents the BBB breakdown. In addition,
it might be useful to characterise the infiltration of adaptive immune cells, such as lym-
phocytes, and their contribution to the cytokine levels in the brain.
Since solTNF-α can also affect neuronal and microglial functions, it would be worth-
while to investigate the contribution of microglial cells in the development and progres-
sion of TLE. Studies with Plexxikon-feeded animals may help to elucidate this question.
Plexxikon transiently depletes exclusively microglial cells and spares macrophages, after
its oral administration. Plexxikon has been shown to maintain BBB integrity, thus low-
ering infiltrating immune cells, decreasing neuroinflammation (Szalay et al., 2016) and
possibly reducing seizure activity.
One hour after SE induction, TNF-α and IL-1β were expressed as in sham-injected
control animals, and yet we found a significant reduction in astrocytic coupling at this
time (Henning et al., unpublished). These results raise the question of the underlying
molecular mechanism, since both cytokine levels are not significantly elevated and there-
fore have hardly any influence on astrocytic uncoupling. A possible explanation is that
cytoskeletal pathology causes retraction of astrocyte processes, even before activation of
the innate immune system occurs. This retraction may lead to the observed reduction
in coupling. Therefore, studying the astrocytic coupling with substances that prevent
cytoskeletal changes, could be a further step in understanding the mechanisms of im-
paired astrocytic GJC at a very early stage after SE.
In our study we could show that the selective inhibition of solTNF-α has a very strong
influence on the progression of TLE. The impact of solTNF-α on the development of
TLE was extensively characterised in an experimental mouse model of TLE. The ad-
ministration of XPro1595 in vivo provided new insights into the mechanisms of the
solTNF-α/TNFR1 signalling pathway underlying the progression of TLE.
Inhibition of TNFR1 signalling cascade has been shown to have anticonvulsant effects
(Balosso et al., 2005; Weinberg et al., 2013). To improve our understanding of the
involvement of the tmTNF ligand and its TNFR2 signalling, it might be useful to
specifically activate TNFR2 by using novel mimetic single-chain TNF trimer ligands.
A combination of solTNF-α inhibition and TNFR2 activation might even slow down the
progression of epilepsy much faster than using only one approach.
Further experiments investigating the role of astrocytic coupling and underlying func-
tional mechanism of XPro1595, will help us to understand the complex progression of
TLE.
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